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CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED  
SQUAMOUS CELL CARCINOMA OF HEAD AND NECK  WITH   
CAPECITABINE AND  WEEKLY CISPLATIN 
Dr.Ramya.A* Prof.Dr.S.Shanmugakumar; Prof.Dr.N.V.Kalaiyarasi; 
Dr.Baskar, Dr.Madhumathi, Dr.Sundaresan, Dr.Prabakaran. 
Dept. of Radiotherapy, Madras Medical College, Chennai. 
AIMS & OBJECTIVES: 
                  To assess the immediate loco regional response rates and acute toxicity in patients 
with locally advanced squamous cell carcinomas of the head and neck in Conventional 
radiotherapy with weekly Cisplatin and Capecitabine. 
MATERIALS AND METHODOLOGY: 
                 Single arm prospective study with 30 consecutive patients with locally advanced head 
and neck cancer presented to the department of radiotherapy, Madras medical college, Chennai. 
All patients were treated with conventional radiotherapy 66Gy along with weekly Inj.Cisplatin 
40mg/m
2 
and T.capecitabine 500mg/m
2 
twice daily along with radiation.  
The immediate loco regional response rates were assessed clinically and radiologically  
6 weeks after concurrent chemo radiotherapy. The toxicity profile of the treatment was assessed 
with RTOG acute morbidity scoring criteria and CTCAE Version 4. 
RESULTS: 
               Among 30 patients, Ca Oropharynx was 9 patients, followed by Ca Hypopharynx 8 
patients, Ca Oral cavity with 7 patients and Ca Supraglottis 6 patients. 73% of patients had 
complete response and 27% had partial response. Toxicities observed in the study were 
Mucositis grade 3 in 5 patients and grade 4 in 2 patients; Skin reactions grade 2 in 2 patients. 
Leucopenia grade 2 in 2 patients. Systemic toxicity diarrhea grade 1 was only in 2 patients. 
There was no renal toxicity, hand foot syndrome in this study. There was no treatment related 
deaths in this study. 
CONCLUSION: 
              Concurrent chemoradiotherapy with Inj.Cisplatin and T.Capecitabine in locally 
advanced squamous cell carcinoma of head and neck cancer is better regimen with manageable 
toxicity with higher complete response rate.  
Key words: concurrent chemoradiotherapy, cisplatin, capecitabine, mucositis,hand foot 
syndrome 
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INTRODUCTION 
Cancer is one of the most dreaded diseases in the world. In olden 
days the word cancer alone aroused fear in common people. In developed 
countries like the United States of America, it is one of the non-
communicable notifiable diseases1. In India, incidence of cancer is rising; 
because of the increasing morbidity and mortality due to cancer, many 
states have made cancer notifiable and it is soon to become the first non-
communicable disease notifiable to the center 
Face is the index of the mind. Head and neck lodges the most 
crucial physiological functions like respiration, nutrition, language and 
expression most important unique feature of our mankind. Also it helps 
us to express our feelings from heart. 
As the life expectancy of the population rises, there is an increasing 
incidence in the trend of cancer in the world. They pose a significant 
health problem especially in developing countries, including India. Due 
to high exposure to smokeless and smoke tobacco among Indian people, 
head and neck cancers in India continues to be a major public health 
problem and it causes significant morbidity and mortality. 
Head and neck region cancers represent a heterogeneous group of 
cancers arising from the mucosa of upper aerodigestive organs, lined by 
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squamous epithelium. It comprises the cancers in the following 
anatomical regions, nasalcavity, nasopharynx, oral cavity, oropharynx, 
hypopharynx, the larynx, the salivary glands and the para nasal sinuses. 
CANCER SCENARIO: 
Every year around 5 million new cases of head and neck cancers 
are diagnosed worldwide2. Being sixth most common cancer in the world, 
it causes devastating effect on the individual by way of functional and 
cosmetic consequences. The head and neck cancer incidence has reduced 
in the developed countries with the awareness that smoking being the 
commonest cause and the subsequent decrease in smokers. Global burden 
rises to 14.1 million new cases and 8.2 million cancer deaths in 20122A. 
 In India, Squamous cell carcinoma of the head and neck is one of 
the commonest cancers in our country due to the widespread use of 
tobacco products in its various forms. Despite the steps taken by our 
government to create awareness with graphic warning labels on the 
tobacco products and a ban on the advertisements for tobacco products, 
Tobacco addiction has now become a common problem among 
youngsters resulting in the incidence of cancer at a very young age.  
 Head and neck cancers in India accounts for about 30% of all 
cancers in the males, constitute 11 to 16% in females. Over 200,000 cases 
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of head and neck cancers occur each year in India. Nearly 80,000 oral 
cancers are diagnosed every year in our country3. 
According to study published in Lancet in March 2012, the cancers 
related to tobacco represented around 42% of male and 18% of female 
cancer deaths in India. The most common fatal cancers in men are oral 
(including lip and pharynx) and lung.53 
In Tamilnadu, MMTR states that most common cancer in men is 
head and neck cancer (19.23%) followed next  by stomach cancer 
(13.98%) and  lung cancer (12.46%). In women, breast cancer is the most 
common (20.87%) followed by cervical cancer (11.46%), stomach cancer 
(8.11%) and head and neck cancer (7.53%). 
In our institute Barnard Institute of Radiology & Oncology, head 
and neck cancers constitute the majority of cases registered in our OPD. 
Majority of them are squamous cell carcinomas (~95%) with other 
histologies making up the remaining. Nearly 75% of them present in the 
locally advanced stage. Only around 20 to 25% of the cases present in the 
early stages. Most of them belong to poor socioeconomic status, tobacco 
users either in smoked form such as cigarettes, beedis or non-smoked 
forms such as pan etc. 
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ANATOMY: 
 The head and neck includes Oral cavity, Nasopharynx, 
Oropharynx, Hypopharynx, Larynx, para nasal sinuses, Nasal cavity, 
Salivary glands and Thyroid gland. This study includes patients only Oral 
cavity, Oropharynx, Hypopharynx and Larynx. 
 The Oral cavity includes Mucosal Lip, Buccal Mucosa, Alveolar 
Ridge, Retromolar Trigone, Floor of the Mouth, Hard Palate and Oral 
Tongue 
Lip:  
The lip begins at the junction of the vermilion border of the skin 
and includes only the vermilion surface. It is well defined into an upper 
and lower lip joined at the angle of mouth. 
Buccal Mucosa: 
 Buccal mucosa includes the membranous lining of the inner 
surface of the cheeks and lips from the line of contact of the opposing lips 
to the line of attachment of mucosa of the alveolar ridge (upper and 
lower) and pterygomandibularraphe. 
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Alveolar Ridge : Mucosa overlying the alveolar process of the mandible 
or maxilla and extends from the mucosal lining in the gingivobuccal 
sulcus; Lower alveolar ridge: extends to the line of free mucosa of the 
floor of the mouth. Posteriorly, to the ascending ramus of the mandible. 
Upper alveolar ridge: from upper gingivobuccal sulcus to the junction of 
the hard palate, posteriorly to upper end of the pterygopalatine arch. 
Retromolar Trigone: is the mucosal covering overlying the ascending 
ramus of the mandible from the last molar tooth to the apex superiorly, 
adjacent to the tuberosity of the maxilla. 
Floor of the Mouth: Semilunar space overlying the mylohyoid and 
hyoglossus muscles extends up to the undersurface of the tongue. Its 
posterior boundary is formed by the base of the anterior pillar of the 
tonsil. The ostia of the submandibular and Sublingual salivary glands lie 
in the floor of mouth. 
Hard Palate: Semilunar area between the upper alveolar ridge and the 
mucous membrane covering the palatine process of the maxillary palatine 
bones. It extends from the inner surface of the superior alveolar ridge to 
the posterioredge of the palatine bone. 
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Oral Tongue: The portion of the tongue which extends anteriorly from 
the line of circumvallate papillae to the undersurface of the tongue at the 
junction of the floor of the mouth. It is divided into the tip, the lateral 
borders, the dorsum, and the ventral surface of tongue. 
PHARYNX: is divided into Nasopharynx, Oropharynx and 
Hypopharynx. 
Oropharynx: this part of pharynx extends from the soft palate to the 
superior surface of the hyoid bone / vallecula. Oropharynx includes base 
of tongue, vallecula, soft palate, uvula, tonsil with anterior and posterior 
tonsillar pillar, glossotonsillar sulci and posterior pharyngeal walls. 
Hypopharynx: Extends from the superior border of the hyoid bone to the 
lower border of the cricoid cartilage. It includes the pyriform sinuses 
(right and left), the lateral and posterior hypopharyngeal walls, and the 
post cricoid region. 
The post cricoid area forms the anterior wall of the hypopharynx. It 
extends from the level of the arytenoids cartilages and to the plane of the 
inferior border of the cricoid cartilage. 
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The pyriform sinus extends from the pharyngoepiglottic fold to the 
cricopharynx and bounded laterally by the lateral pharyngeal wall, 
medially by aryepiglottic fold and the arytenoid and cricoid cartilages. 
The posterior pharyngeal wall extends from the level of the 
superior surface of the hyoid bone to the inferior of the cricoid cartilage. 
LARYNX: composed of several cartilages connected by ligaments and 
muscles. It is divided anatomically into the Supraglottic, Glottic, and 
Subglottic regions.  
 The Supraglottic larynx consists of the epiglottis, false vocal cords, 
ventricles, aryepiglottic folds, and arytenoids; the arytenoids are 
cartilages that articulate on the cricoid. 
The glottis includes the true vocal cords and the anterior 
commissure.  
The subglottis is 2 cm long and extends from 5 mm below the free 
edge of the true vocal cords to the upper margin of the first tracheal ring. 
The preepiglottic space is bounded by the epiglottis posteriorly, the 
hyoepiglottic ligament and vallecula superiorly, and the thyroid cartilage 
and thyrohyoid membrane anteriorly and laterally. 
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RISK FACTORS: 
The etiological factors of head and neck cancers point to the impact 
that lifestyle changes in past century had on our health. The principle risk 
factors are tobacco and alcohol. 
TOBACCO: 
 According to National Cancer Institute reports 85% of patients 
with head and neck cancers have a history of tobacco usage. There exists 
a dominant and strong relationship between tobacco usage and squamous 
cell carcinoma of the head and neck (SCCHN). 
1.SMOKING: 
 Development risk of SCCHN is directly correlated to duration and 
intensity of smoking4.Smoking tobacco in the form of beedis, cigarettes, 
cigars, chutta/cheroot, dhumti, hookah and chillum is prevalent in India. 
Certain populations especially in coastal areas practice reverse smoking. 
About 50% men and 11% women between 15 – 49 years of age practice 
smoking in India5,6 
Cigarettes are the main form of consumable tobacco worldwide.  
Beedis which consist of a small amount of tobacco flakes wrapped in 
temburni leaf with a colored string at one end are very famous in India. 
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The puff` rate per minute of a beedi is higher than that of an unfiltered 
cigarette which is responsible for the more carcinogenic load of beedis. 
Nicotine is the major psycostimulant in tobacco. It increases the 
dopamine levels in nucleus accumbens and causes an incentive value and 
makes the habit to be repeated again and again causing addiction. The 
major carcinogens in tobacco causing cancer are PAH (polycyclic 
aromatic hydrocarbons), NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol] and NNN(N1-nitroso nor nicotine). 
SMOKELESS TOBACCO: 
Globally there is a 60% increase in alternative nicotine delivery 
systems like snuff, lozenges. Betel quid is extensively used in India. It is 
also called as pan which consists of pieces of areca nut, tobacco and 
slaked lime. Added to this are spices, cardamom, cloves, according to the 
local preferences and are varyingly called as gutkha, zarda, mawa, 
khaini9. 
Oral sub mucous fibrosis is produced by chewing areca nut. Smokeless 
tobacco chewing is not an alternative to smoking tobacco. Indeed the 
content of nicotine and the carcinogens are manifold in smokeless 
tobacco7,8. 
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ALCOHOL: 
Alcohol has synergistic effect with tobacco. Duration, intensity and 
concentration of alcohol consumption directly correlates with oral cavity 
Cancer.10,11 
          A meta-analysis from 26 studies of oral and pharyngeal cancers 
found that consumption of  25, 50, or 100 g pure alcohol/day1 was 
associated with a pooled relative risk (RR) of 1.75, 2.85, and 6.01, 
respectively, of oral and pharyngeal cancer13,14Alcohol consumption also 
leads to immunosuppression, alcohol related diseases, altered behavior, 
unhealthy dietary pattern, and unstable emotional balance. All these 
factors have impact on cancer treatment and survival.  
HUMAN PAPILLOMA VIRUS: 
HPV infection is proved to be one of the causative factor in 
SCCHN. 
HPV prevalence is about 30-35% observed in head and neck 
cancers, with  
11 
 
HPV-16 being detected in 60- 90% of infected cancer cases.14,15 
HPV prevalence has been found to be highest in oropharynx 
tumors(palatine tonsil),less common in the oral cavity14-16. 
The oncogenesis of SCCHN by HPV is by transformation of 
epithelial cells by viral oncoproteins E6 and E7 which inactivate the 
tumor suppressor genes p53 and pRbin the host cell leading on to 
increased cell proliferation and inhibition of apoptosis.17-19 
HPV positive oropharyngeal cancers have characteristic features like 
- Young patients, 
- Nonsmokers 
- Non alcoholics 
- Present with locally advanced disease with large T and N stage 
- Often with basaloid histology  
- Poorly differentiated 
-Sexually transmitted cancer due to oral sexual activity 
-Better prognosis due to sensitivity to radiotherapy and chemotherapy has   
compared HPV negative SCCHN. 
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Figure no:1 HPV biological action 
 
OTHER RISK FACTORS: 
Diet deficient in antioxidants has been implicated to cause cancer 
in about 10% cases, spicy food consumption, sharp teeth, wood dust, heat 
fumes, sub mucus fibrosis etc 
Plummer Vinson syndrome due to chronic iron deficiency and its 
association with post cricoid web can produce hypo pharyngeal SCCHN. 
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Chronic actinic exposure can produce cancer of lip. 
PRECANCEROUS CONDITIONS: 
Leukoplakia, Erythroplakia, Submucous fibrosis, Lichenplanus, 
Epidermolysisbullosa, Discoid lupus erythematosus etc21. 
Leukoplakia:  
The most common premalignant lesion of the oral cavity. It is 
defined as a white mucosal patch or plaque,usually resolves with 
cessation of smoking. 
Erythroplakia: 
Reddish discolouration of the mucosa, 15-20% increased risk of 
cancer.  
In a study done by Northern Ireland22 states that, only 15% of 
dysplastic lesions and 1% of non-dysplastic lesions(epithelial hyperplasia, 
lupus etc) turn to neoplasia. 
INHERITED CONDITIONS like Fanconi Anemia (FA), Ataxia 
Telangiectasia, Blooms Syndrome, & Li-Fraumeni Syndrome as 
increased risk of HNSCC.23 
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HISTOLOGICAL CLASSIFICATION: 
       Squamous cell carcinoma constitutes 90 - 95% of the head and neck 
cancers. 
Remaining 5% are adenocarcinoma, verrucous carcinoma, minor 
salivary gland tumors, melanomas, adenoid cystic carcinoma, lympho-
epitheliomas, and lymphoma, sarcoma, extra medullary plasmocytoma. 
        With respect to grades of differentiation based on keratinization, 
squamous cell carcinoma as three types; 
Well differentiated : >75% keratinized 
Moderately differentiated : 25-50% keratinized 
Poorly differentiated: <25% keratinized. 
The prognostic and predictive significance of histological differentiation 
is well established24 
SYMPTOMS:  
Most common presenting symptom is ulcer(or ulceroprolifertive 
lesion) followed by  pain, difficulty in swallowing (dysphagia), pain 
during swallowing (odynophagia), difficulty in breathing (dyspnea), 
change in voice, and neck swelling because of lymph nodal involvement. 
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Other generalized symptoms are cough, weight loss, loss of appetite may 
cause further detoriation with treatment like concurrent chemoradiation. 
Nutritional status of the patient plays a major role in treatment outcome. 
PROGNOSTIC FACTORS: 
Unfortunately in India around 60% of head and neck cancers 
present in locally advanced stage (III & IV). In our institute 65- 70 % of 
total head and neck cancers are in the locally advanced stage. The reason 
may be due to poor socioeconomic status, lack of awareness and 
education, inaccessibility to treatment areas and fear of mutilating 
surgery25. Many psychosocial factors like beliefs like ‘cancer a curse’, 
‘ill-fated to have cancer’, ‘trivial ulcers in the mouth are self-limiting’ 
and also the fear that the prolonged treatment will render the family 
stressful. Thus most of our patients present with advanced T stage with 
Lymph node involvement in which case single modality treatment is not 
possible. 
Even with combined modality treatment local recurrences occur in 
40-50% of the patients. 
The following prognostic factors play a major role in locoregional 
control.26 
16 
 
TUMOR SIZE:   
T stage major prognostic factor. Advanced T stage have poor prognosis. 
NODAL INVOVLMENT: reduces the survival by 50%. 
TUMOUR SITE: early Ca Larynx as good prognosis than oral cavity 
and hypopharynx. 
Other factors like  
Perineural invasion,  
Postoperative positive or close margins,  
Extra capsular nodal extension,  
Depth of invasion. 
MOLECULAR BIOMARKERS: 
EGFR: 
Studies show that 80- 95% of the squamous cell carcinomas of the 
head and neck are associated with over expression of EGFR 
receptors.27,28Activated, EGFR leads to cell proliferation, inhibits 
apoptosis, affects cell differentiation, increases cell motility, stimulates 
angiogenesis and is known to induce metastasis. This gives a therapeutic 
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target in manipulating receptor pathways in cancer cells with targeted 
agents, monoclonal antibodies, like cetuximab as shown benefit in the 
advanced stages.29,31 
TYROSINE KINASES: 
Downstream kinases responsible for various functional pathways – 
proven response with manipulating targeted agents like geftinib35, 
erlotinib, dasatinib.30 
P53 MUTATION:  
               Most common gene mutation observed in head and neck 
cancers. This p53 mutation is associated with worse prognosis because 
this gene is involved in cell cycle regulation and apoptosis. Poor response 
to chemoradiotherapy. 
Other mutations include Cyclin D1, Bcl-2, STAT1 and 3, ERCC1. 
HEAD AND NECK CANCER TREATMENT OVERVIEW: 
             Cancers of Head and neckhasa multimodality treatment which 
includes Surgery, Chemotherapy, Radiotherapy and upcoming targeted 
therapy. The main outcome should be locoregional control with function 
preservation.  
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SURGERY: 
               Emerging from the history of cancer treatment surgery plays a 
major role.    Surgery has been the primary modality used in the treatment 
of head and neck cancers, since then. But surgery results in disfigurement 
and loss of function too. Though plastic surgery as developed in recent 
years with less morbid  procedures, most of the  patients do not opt for it. 
              The head and neck squamous cell carcinoma can be  
Resectable, Unresectable or Inoperable 
RESECTABLE: 
The resection of advanced cancers of oral cavity, oropharynx, hypo 
pharynx or larynx is by an enbloc resection to attain negative surgical 
margins. An adequate margin of 1.5 cm to 2cm is required to obtain a 
clear frozen section. Any suspected margin of < 2 cm has to be examined 
by a frozen section.  
A clear margin is defined as a distance of ≥ 5 mm from the 
resected margin to the invasive tumor. A close margin is a distance of  
<5mm. Primary tumor is usually approached through a trans-oral, 
transcervical or, through mandibulectomy. 
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NECK DISSECTION: 
 The anatomy of neck node levels should be known before lymph 
node dissection. There are no capillary lymphatics in head and neck 
epithelium so tumor must penetrate lamina propria before lymphatic 
invasion to occur. Thus the involvement of lymph nodes in head and neck 
indicate that the tumor is locally advanced.  
 The lymph node levels of the neck are divided into seven levels. 
Level I include Iasubmental nodes and Ib submandibular nodes. 
Level II upper jugular nodes 
Level III middle jugular nodes  
Level IV lower jugular nodes. 
Level V as posterior triangle lymphnodes.(spinal accessory chain lymph 
nodes) 
Level VI pretracheal nodes, prelaryngeal and para tracheal nodes  
Level VII mediastinal nodes. 
Other regional nodes include 
Suboccipital 
Retropharyngeal 
Parapharyngeal 
Buccinator (facial) 
Preauricular 
Periparotid and intraparotid 
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 Lymph node levels drain a particular site in head and neck. So 
surgery can be planned depending on this nodal region involvement.  
Oral Cavity: 
The primary site lip drains into Level I nodes with central part to 
submental nodes and angle of mouth to submandibular nodes. In case of 
oral cavity tumors mainly Level Ib submandibular and Level II nodes. 
Oral tongue as unique lymphatic drainage with Level Ib, II _IV; 
especially in lymphatics of tongue there is crossing over and thus bilateral 
nodal involvement is possible. Also tongue can have direct involvement 
of level IV node without Level Ib,II nodes involvement. 
Oropharynx mainly drains to Level II and III involvement. 
 In case of Nasopharynx retropharyngeal lymph nodes are involved 
in 94% of cases or Level II in 90% of the patients. But it can involve 
Level II –V group of nodes.  
In case of Hypopharynx bilaterality is common with involvement 
of Level II – IV group of nodes. Larynx – supraglottis drains to Level II – 
IV. 
Other areas like paranasal sinses, middle ear, vocal cords have 
fewer or no lymphatics. 
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Figure no:2 neck node levels 
In a classic radical neck dissection, the superficial and deep 
cervical fascia with its enclosed lymph nodes (levels I to V) is removed in 
continuity with the sternocleidomastoid muscle, the omohyoid muscle, 
the internal and external jugular veins, cranial nerve XI, and the 
submandibular gland. The radical neck dissection can be modified to 
spare certain structures with the intent of decreasing morbidity and 
improving functional outcome without compromising disease control39.  
There are three main types of modified radical neck dissections: 
type I—cranial nerve XI is spared; type II—cranial nerve XI and the 
internal jugular vein are spared; type III (functional)—cranial nerve XI, 
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the internal jugular vein, and the sternocleidomastoid muscle are spared. 
Selective neck dissections include the resection of lymph node levels that 
are at greatest risk for nodal metastatic spread. Types include the lateral, 
posterolateral, and supraomohyoid, which include resections of lymph 
node levels II–IV, II–V, and I-III, respectively.32,33 
A modified or selective neck dissection is recommended for the 
cN0 neck, for selected clinically positive necks (mobile, 1–3 cm lymph 
nodes), and for removing residual disease after RT when there has been 
excellent regression of N2 or N3 disease. 
UNRESECTABLE: 
 In a condition when adequate surgical clearance is not achievable, 
tumor spread to inaccessible areas like base of skull, infiltration into 
carotid artery, fixed nodes surgery is not an option. 
INOPERABLE: 
In such cases patient general condition is poor, metastatic disease 
such that surgery is not possible. 
 Patients completed chemo radiotherapy with residual disease may 
be amenable to Salvage surgery. 
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RADIOTHEAPY: 
 The concept of organ preservation as emerged ever since the 
Radiotherapy as proven its role in the treatment of cancer. Mainly in the 
Head and neck tumors it provides the major effect of organ preservation. 
 The discovery of X-Rays by William Roentgen in 1895. The first 
head and neck cancer to be cured by Fractionated Radiotherapy was in 
1928 and since then various modalities and combinations with 
chemotherapy have been tried to increase the cure rate in these cancers. 
Radiotherapy can be administered either Pre operatively, Post 
operatively or it can be definitive treatment with radiation alone in early 
stage tumors. 
          In case of postoperative Radiotherapy it should be administered 
after 4-6 weeks of surgery.  Indications for postoperative radiotherapy are 
 Advanced T stage,  
 Multiple node positivity and  
 Perineural or lymphovascular invasion. 
 Post-operative chemo radiation is indicated in the case of positive 
margins and extra capsular extension. 
 The radiotherapy can be administrated in different types like 
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CONVENTIONAL FRACTIONATION: 
                   As definitive modality dose of 66-70 Gy is recommended to 
the gross disease and 45 - 60 Gy to the subclinical disease. In a schedule 
of 2Gy per fraction 5 days a week. 
ALTERED FRACTIONATION: 
Accelerated Radiotherapy: 
Decreases the overall treatment time so that the tumor cells regenerate 
less during the treatment and hence better loco regional control is 
achieved36. 
Pure accelerated radiotherapy: 
There is a decrease in the overall treatment time but no change in the total 
dose or fraction size. 
Hybrid accelerated fractionation: There are three types. 
Type A: Drastic reduction in overall treatment time and a considerable 
decrease in the total dose. 
Type B: Treatment time is decreased, total dose remains the same with 
an added break in between treatment(67.2 Gy in 42 fractions of 1.6 Gy 
twice daily over 6 weeks, including a 2-week break). 
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Type C(Accelerated concomitant boost): Total dose is same; overall 
treatment time is reduced with concomitant boostregimen (72 Gy in 42 
fractions over 6 weeks, with 1.8 Gy daily for the first 3.6 weeks and 1.8 
Gy [large field] plus 1.5 Gy [boost field], 6 hours apart, for the last 2.4 
weeks)(36). 
Hyper Fractionated Radiotherapy: Dose of radiation is increased, dose 
per fraction is significantly reduced, the numbers of fractions are 
increased and overalltreatment time is significantly unchanged(81.6 Gy in 
68 fractions over 7 weeks, with 1.2 Gy given twice daily) 
PALLIATIVE RADIOTHERAPY: 
               In patients who presents with very advanced stage, such cases 
cure is not possible as effort to alleviate the symptoms. Mostly given in 
Hypofractionated schedule. 
CHEMOTHERPY:  
               Role of chemotherapy with radiation is proved in various 
trials37,38The MACHNC trial as proved overall survival benefit of 4% 
with addition of chemotherapy in a patient treated with surgery or 
radiotherapy. 
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Chemotherapy can be administered either as Induction, Concurrent or 
Adjuvant setting. 
INDUCTION CHEMOTHERAPY: 
             It has proved that induction chemotherapy reduces distant 
metastases but no difference in overall survival. 
The neoadjuvant setting as an organ preservation approach in 
laryngeal cancers-the Veterans Affairs trial41 used chemotherapy in the 
neo adjuvant setting compared to concurrent chemoradiation to achieve 
organ preservation. . The use of induction chemotherapy using standard 
doses of cisplatin and 5 FU in various trials has shown a response rate of 
60 to 90 % including 25 – 30 % complete response. It also decreased the 
incidence of distant metastasis probably because of the effect on micro 
metastasis in the circulation. But it failed to demonstrate any 
improvement in the survival. The recent phase III randomised trial 
DeCIDE trial which uses induction chemotherapy using docetaxel, 
cisplatin and 5FU followed by concurrent chemo radiation did not 
demonstrate any survival benefit from induction chemotherapy compared 
to concurrent chemo radiation.42 
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ADJUVANT CHEMOTHERAPY:   
In case of postoperative setting with positive margins and 
extracapsular extension. Adjuvant chemo as a theoretical benefit of 
eradicating the sub clinical disease left behind after chemo radiation, also 
postulated that it sterilizes the micro metastasis present in the circulation 
and thereby prevent distal recurrence rate and improve overall survival 
rate. The increased sensitivity of minimal residual disease to anticancer 
drugs has been shown by cell cycle and growth fraction studies. 
Unfortunately these theoretical benefits are not proved by any 
randomised control trials and supportive evidence forthe routine use of 
adjuvant chemotherapy is far from definitive. 
CONCURRENT CHEMORADIATION: 
            In the path of concurrent chemo radiation, initially trials was done 
with Bleomycin, Mitomycin, Cisplatin etc. But has the results of the 
Meta-analysis MACHNC 37 as clearly proved that Cisplatin as the drug of 
choice in concurrent chemo radiation. This trial has shown an absolute 
benefit of 6.5% +1% at the end of 5 years in overall survival with 
concurrent chemo radiation as compared to 2 % benefit with Induction 
Chemotherapy. 
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           Thus Cisplatin is used in various trials in different regimens. 
Cisplatin in three weekly or weekly regimens can be used in any way the 
Cisplatin cumulative dose should be kept equal to or above 210mg 
(machnc-37). 
PALLIATIVE CHEMOTHERAPY:  
          In head and neck cancers many different drug regimen as tried but 
no single agent has proven superior to others. 
TARGETED THERAPY: 
           As already stated that EGFR receptors in over expressed in 85-
90% of head and neck cancers. Inhibitors of EGFR like the monoclonal 
antibody Cetuximabhas used in many trials. The EXTREME trial43 
demonstrated that the addition of cetuximab to Cisplatin and 5 FU 
regimens in metastatic and recurrent head and neck cancer resulted in an 
improved overall survival. The landmark trial by Bonner et. Al44 showed 
that addition of cetuximab concurrently to radiotherapy in locally 
advanced head and neck cancers resulted in a significant improvement in 
loco regional control and median OS. 
       The use downstream kinases inhibitors like geftinib and erlotinib 
have not shown any added benefit with its addition to the standard 
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therapies. Recently COX-2 inhibitors, farnesyl inhibitors, and proteasome 
inhibitors are under study for head and neck cancer. 
 PREVENTION OF HEAD AND NECK CANCER- upcoming 
concept: 
          As there is a concept of Field Cancerization  which states that the 
entire upper aero digestive tract is subject to subcellular injury by  
exposure to carcinogens, hence susceptible to cancer formation. Thus a 
person with malignancy in upper aerodigestive is prone for 20% 
increased lifetime risk of second primary tumor. This may be due to 
genetic alterations in time. This forms the basis of chemoprevention. 
          Many trials with different chemopreventive agents has been tried. 
Mainly with Cis-Retinoic acid; RTOG ( The Radiation Therapy 
Oncology Group ) trial with 13-cis-retinoic acid in a multi-institutional 
setting, consisting 1400 patients with stage I or II cancer were accrued. 
Unfortunately, this trial was negative and did not show any benefit to low 
dose isotretinoin in the prevention of second primary cancers.Other 
chemo preventive agents being investigated are green tea extracts, 
curcumin extracts, soybeans etc. 
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Other methods of prevention will include: 
1. Awareness regarding tobacco products. Regulations controlling 
the sale of tobacco products. 
2. Awareness about sexual practices like oral sex resulting in HPV 
infection. 
3. Abstinence from alcohol 
4.  Good oral hygiene 
           5. Good nutrient rich diet, fresh fruits and vegetables 
RATIONALE OF THIS STUDY: 
             As the MACHNC trials clearly proved the benefit of adding 
chemotherapy concurrently with radiation shows improvement in overall 
survival of 8% at the end of 5yrs.Concurrent chemo radiation forms the 
treatment of choice in Locally Advanced Squamous cell carcinoma of 
Head and Neck (SCCHN)37. 
            As the trials established Platinum based schedule gave best 
results, there is still ongoing search for better regimen with concurrent 
chemo radiation to improve immediate loco regional control and later 
overall survival. 
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Multiple single gents and various combination of drugs are being tested 
in trials all over the world. 
Cisplatin (Cis-diamminedichloroplatinum):  
Cisplatin reacts on two different sites on DNA to produce cross-links 
like intrastrand (>90%) or interstrand (<5%).  
Formation of DNA adducts results in inhibition of DNA synthesis, 
function and inhibition of transcription. 
Binding to nuclear and cytoplasmic proteins may result in cytotoxic 
effects.  
Cisplatin and 5FU: 
Cisplatin and 5FU have been used in most trials of concurrent 
chemoradiation. 5-FU has adverse effects such as oral mucositis, 
diarrhoea which is exaggerated due to additive effect of radiation, and 
myelo suppression; these adverse effects can result in treatment-related 
hospitalization or mortality, thereby diminishing quality of life and 
reducing treatment compliance.  
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Cisplatin and Capecitabine: 
                   The oral fluoropyrimidine Capecitabine prodrug, itself is 
inactive; it was rationally designed to preferentially generate 5-FU in 
tumour tissue and mimic continuous infusion of 5 -FU. This selectivity is 
achieved through exploiting the significantly higher activity of thymidine 
phosphorylase (TP) in many tumour tissues compared with healthy 
tissue.47 
METABOLISM OF CAPECITABINE:         
Activation to cytotoxic forms involves 3 successive enzymatic steps.46-48 
 
Metabolized mainly in liver by carboxylesterase enzyme into 5'-deoxy-5-
fluorocytidine (5'-DFCR) and cytidine deaminase  in liver and tumor   
tissues converts to 5'-deoxy-5-fluorouridine(5'-DFUR) finally the enzyme 
thymidine phosphorylase mainly in tumor tissue converts into                          
5-FluoroUracil 
 
 
 
 
 
33 
 
Metabolized mainly in liver 
   
      Capecitabine  
 
carboxylesterase enzyme    liver 
 
5'-deoxy-5-fluorocytidine (5'-DFCR)  
 
cytidine deaminase   liver and tumor       tissues 
 
5'-deoxy-5-fluorouridine (5'-DFUR) 
 
enzyme thymidine phosphorylase            mainly in tumor tissue 
 
5-FluoroUracil 
 
 
MECHANISM OF ACTION OF CAPECITABINE: 
 The 5-FU metabolite FdUMP - Inhibits the target enzyme 
thymidylate synthase.  
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 5-FU metabolite FUTP incorporates into RNA causing 
alterations in RNA processing and translation. 
DNA INHIBITION: 
 5-FU metabolite FdUTPincorporates into DNA results in inhibition 
of DNA synthesis and function. 
 Accumulation of dUMP due to inhibition of thymidine synthase 
causes subsequent misincorporation of dUTP into DNA, results in 
inhibition of DNA synthesis and function. 
 
Capecitabine metabolism leads to 2.9-fold higher 5-FU concentrations 
in malignant compared with non-malignant tissues49. This results in a 
higher therapeutic index for Capecitabine compared with other 
fluoropyrimidines50,51. 
Rationale of dose reduction of Capecitabine: 
Trials have shown that MTD (maximum tolerated dose) of Capecitabine 
concurrently with radiation was 500mg /m2twice daily in locally 
advanced head and neck squamous cell carcinoma 52. As a radiosensitizer 
Capecitabine increases the efficacy of radiation and cisplatin. Twice daily 
doses results in prolonged exposure of 5-FU. Also radiation up regulates 
the expression of the enzyme Thymidine Phosphorylase improves the 
efficacy of Capecitabine. 
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Since loco regional failure is the most common type of failure after 
therapy in locally advanced head and neck cancer, a regimen of 
concurrent chemoradiation with weekly cisplatin and Capecitabine daily 
has the potential to improve this without the systemic toxicity of full-dose 
chemotherapy. 
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CANCER TREND IN CHENNAI: 
 The trend of head and neck cancer  from Madras metropolitan 
Cancer Registry clearly shows the rising incidence in a decade. 
 
TREND OF HEAD AND NECK CANCER IN MMTR  
Table no:1 Cancer trend 
 
Head and Neck  SITES 
          
PERIOD MALE FEMALE 
  CIR ASR CIR ASR 
1983-87 16.3 24.8 9.4 13.7 
1988-92 19.0 30.0 9.9 14.7 
1993-97 19.5 25.9 8.2 10.5 
1998-02 20.7 25.0 8.7 10.3 
2003-05 22.2 25.2 9.3 10.8 
2006-08 22.9 25.2 9.3 10 
2009-10 25.2 26.6 9.4 10.2 
          
 
ASR: AGE STANDARDIZED RATE PER ONE LAKHS 
POPULATION. 
CIR: CRUDE INCIDENCE RATE PER ONE LAKHS POPULATION. 
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Table no: 2, Head and neck cancer site (1) 
         
Chennai   2003-05   2006-2008   
Site CIR ASR CIR ASR 
  Male Female Male Female Male Female Male Female 
Lip 0.3 0.1 0.3 0.2 0.2 0.2 0.2 0.2 
Tongue 5.2 1.7 5.7 2.0 5.4 1.9 5.7 2.1 
Mouth 5.1 4.2 5.7 4.9 6.6 4 7.1 4.5 
Oropharynx 2.7 0.4 3.1 0.4 1.5 0.2 1.7 0.2 
Nasopharynx 0.6 0.4 0.7 0.4 0.7 0.3 0.7 0.3 
Hypopharynx 3.7 1.6 4.3 1.8 4.2 1.9 4.8 1.9 
Pharynx Uns 0.5 0.2 0.5 0.2 0.6 0.3 0.7 0.3 
Larynx 4.1 0.7 4.9 0.9 3.7 0.5 4.3 0.5 
Total 22.2 9.3 25.2 10.8 22.9 9.3 25.2 10 
          
 
 
Table no:3 Head and neck cancer site (2) 
 
Chennai   2009-2010   
   
 
 
Site CIR ASR 
      Male Female Male Female 
    Lip 0.4 0.4 0.2 0.2 
    Tongue 6.5 6.7 1.9 2.0 
    Mouth 7.4 7.6 4.4 4.8 
    Oropharynx 1.5 1.7 0.2 0.2 
    Nasopharynx 1.0 1 0.3 0.4 
    Hypopharynx 3.5 3.9 1.8 1.9 
    Pharynx Uns 0.6 0.6 0.2 0.2 
    Larynx 4.3 4.7 0.4 0.5 
    Total 25.2 26.6 9.4 10.2 
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LITERATURE REVIEW 
 
As the history of cancer and its treatment emerged in concept from 
the late 19th century, newer techniques and combination of chemotherapy 
with radiation as proved its importance in loco regional control and 
progression free survival. 
 
The use of Concurrent chemo radiotherapy depends upon the tumor 
radiobiology and physics. Surgery followed by postoperative 
radiotherapy was the standard approach in the case of locally advanced 
resectable head and neck cancers. 
 
Conventional fractionation was considered as the best balance 
between tumor kill and normal tissue toxicity. It refers to a radiation dose 
of 2 Gy per fraction, five days a week, up to a total dose of 66-70 Gy55. 
This schedule was the first to be tried in the field of Radiotherapy and 
followed till date.   
 
ALTERED FRACTIONATION IN RADIOTHERAPY:  
EORTC trial by Horriet et al in 1992 - this trial compared 
conventional fractionation, 70Gy in 2Gy per fraction, 35-40# in 7-8 
weeks, to hyperfractionation of total 80.5 Gy in 70 fractions in 7 weeks as 
2 fractions of 1.15Gy per day. Patients included were T2-T3 
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oropharyngeal carcinoma, N0, N1 disease. In the final analysis it was 
found that the local control was significantly higher in case of 
hyperfractionation. Also at 5 years, 59% of patients had locoregional 
control in this arm compared to 40% in the conventional fractionation 
arm. This trial showed that the treatment regimen is an independent 
significant prognostic factor for loco regional control, which resulted in 
improved survival, without a significant difference in late toxicity.56 
 
Another fractionation schedule using six fractions per week instead 
of five fractions showed improved tumor response. DAHANCA 6 and 7 
randomized controlled trial showed the benefit of short treatment time 
with six fractionation per week –due to the promising results of this trial, 
this schedule became the standard of management in Denmark. 
According to this trial the 5-year locoregional control rates were 70% vs 
60% for the six fraction and five-fraction groups. The primary control 
was good but lymph nodes does not show any added benefit. This trial as 
increased acute toxicity but it was transient. (57) 
 
           RTOG 9003 trial compared hyperfractionation and two forms of 
accelerated fractionation to standard fractionation radiotherapy. The 
hyperfractionation arm delivered 1. 2 Gy/fraction bid for 5 days/week to 
81.6 Gy/68 fractions/7 weeks; the accelerated fractionation included split 
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at 1.6 Gy/fraction bid, 5 days/week, to 67.2 Gy/42 fractions/6 weeks 
includes a 2-week rest after 38.4 Gy and another form of acceleration 
with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 
Gy/fraction/day to a boost field as a second treatment daily for the last 12 
treatment days to 72Gy/42 fractions/6 weeks. Hyperfractionation and 
accelerated fractionation with concomitant boost showed significantly 
better local-regional control than standard fractionation36. 
 
      Although Hyperfractionation improves loco regional control, this 
occurs at the cost of increased acute toxicity which results in treatment 
breaks increased hospital stay. 
Sequencing Chemotherapy with Radiation: 
Chemotherapy provides benefit depending on the time of its 
addition with Radiation. The radiobiological basis of combining 
Chemotherapy with Radiation  is to obtain maximum therapeutic benefit. 
Tumour cells have accelerated cell proliferation, hypoxia and acidity 
which are not present in normal cells. Similarly assessment of various 
mechanisms of resistance to radiation and different chemotherapeutic 
agents are also important to be considered. 
Spatial cooperation: in this case radiation acts loco regionally and 
chemotherapy at a distant site, without any overlap.  
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Independent toxicity: the chemotherapy drugs given may have a different 
toxicity profile and it does not increase radiation reactions.  
Enhancement of tumor response: in this case the ability of chemotherapy 
to enhance the radiation response is exploited. This resultin better tumor 
kill based on additive action. This however, does not include the 
cytotoxic action of the drug itself but only its radio sensitizing property, 
to prevent excess normal tissue toxicity. 
If the overall cell killing in the combination treatment is 
contributed by individual cytotoxicity of the drug and individual effect of 
the radiation, then it is called additive effect.  
If the cell killing in combined modality is greater than the cell 
killing by individual cytotoxic agents, then it is called as supra additive 
effect. This is possible when chemotherapeutic agents interact with 
radiation and potentiates the effect of later. 
Inhibition of tumor repopulation: only in case of concomitant 
Chemoradiotherapy.  
Protection of normal tissue: through administrationof agents which 
selectively prevent normal tissue damage 
Improved tumor oxygenation: because of increased cell kill, leading to 
better local control. 
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     There are numerous trials describing the time of Chemotherapy 
introduction with Radiation. 
Induction chemotherapy: 
The Department of Veterans Affairs Laryngeal Cancer study 
Group conducted a prospective randomised control study in locally 
advanced laryngeal cancer. The aim of this study was to compare the 
option of induction chemotherapy followed by radiotherapy with surgery 
reserved for residual or recurrent lesions is a feasible alternative to 
surgery followed by postoperative radiotherapy. Patients in the control 
arm received three cycles of induction chemotherapy using cisplatin and 
5 fluorouracil. The patients were assessed after two cycles of 
chemotherapy. Any patient who failed to attain at least a partial response 
was taken up for immediate surgery followed by radiotherapy. 
Responding patients were allowed to complete three cycles of 
chemotherapy followed by definitive radiotherapy.34 
The results of the trial showed that overall survival was same in both 
arms. The 3 year survival rate was 53%. The loco regional recurrences 
were greater in the control arm (12% vs 2%), but since salvage surgery 
was done in recurrent cases the overall survival was not compromised. 
Another interesting result is distant relapses were decreased in the chemo 
arm (11 % vs 17 %). But despite decrease in distant relapses overall 
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survival could not be improved. 64% of the patients recruited in the 
chemotherapy arm retained functional larynx.The authors concluded that 
in view of the high rate of local recurrences in the case of chemotherapy 
arm more effective local therapy is needed to achieve larynx preservation.  
 EORTC/TAX 323 (Vermorken et al. 2007) in this study 358 
patients with stage III–IV head and neck cancer  which was unresectable 
were randomized toTPF (docetaxel/cisplatin/5-FU) vs. PF (cisplatin/5-
FU) induction chemotherapy followed by RT alone, delivered with 
conventional(66 Gy) or hyperfractionated (74 Gy) RT. Induction chemo 
with TPF increased median survival from14.5 to18.8 months, but 
increased hematologicaltoxicity and chemo-related death (2.3 vs. 5.5%). 
10 -15% of patients after induction chemotherapy were unfit to receive 
Radiation in this study.58 
         Thus role of Induction chemotherapy followed by Radiation is 
acceptable only in selected patients prone for distant recurrences. This 
benefit can be achieved with the compensation of loco regional 
recurrence. 
ADJUVANT CHEMOTHERAPY: 
           Adjuvant chemotherapy in Head and Neck following surgery is 
less studied. 
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Intergroup study 0034 used postoperative cases were randomized 
in into two arms. Study arm had  3 days of Cisplatin (100mg/m2), 21 day 
cycle and infusional 5 fluorouracil(1000mg/m2/day for 5 days, followed 
by radiation dose of 50-60 Gy Vs control arm had radiation alone without 
chemotherapy. There was no improvement  locoregional control or 
overall survival but the incidence of distant metastasis decreased 
significantly from 30% to 20%.  
RTOG 95–01trial with resectable tumors of the oral cavity, 
oropharynx, larynx, or hypopharynxincludes 459 patients who had 2 
involved lymph nodes, nodal extracapsular extension, or positive margin 
randomized to postoperative RT (60–66Gy) vs postoperative 
chemoradiotherapy (60–66 Gy and cisplatin ×3cycles). This study was 
published by Cooper et al in 2004. The results were Chemo-RT improved 
2-year Disease Free Survival (43→54%), Loco Regional Control 
improved from72% to 82%, and improved OverallSurvival (57→63%), 
but hadincreased grade 3–4 toxicity (34→77%).59 
EORTC 22931published by Bernier et al in2004, this trial 
included 
334 patients with resectablestage III/IV oral cavity, oropharynx, larynx, 
and hypopharynx cancer were randomized to postoperative radiotherapy 
(66 Gy) Vs postoperative chemoradiotherapy (66 Gy and cisplatin 100 
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mg/m2 on days 1, 22, 43). Allpatients received 54 Gy to the low-risk 
neck.Chemo-RT improved 3/5-year Disease Free Survival 
(41/36→59/47%), 3/5-year Overall Survival (49/40→65/53%), and 5-
year Loco Regional Control (69→82%), but increased grade 3–4 toxicity 
(21→41%).60,61 
Trials conducted by EORTC and RTOG, both showed post-
operative chemo radiotherapy as improved Disease free survival and loco 
regional control but with increased grade 3&4 toxicity. 
CONCURRENT CHEMORADIATION: 
 Concurrent chemoradiation in locally advanced head and neck 
cancer, the history tracks down to the era when Inj. Mitomycin, 
Inj.Bleomycin were used with Radiation. Initial trials done by NCOG, 
EORTC showed improvement in loco regional control and overall 
survival. Also there are trials with single agent Inj.methotrexate shows 
improve in loco regional control. 
 
But with more understanding of the tumor radiobiology, 
radiosensitizers like 5- Fluorouracil and Cisplatin, either alone or 
together, have been tried in many studies and proved as effective & 
potent chemotherapy drugs to combine with radiation. 
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META-ANALYSIS OF CHEMOTHERAPY IN HEAD AND NECK 
CANCER (MACH-NC):  
            The first part of this landmark meta-analysis which was published 
in the year 2000by Pignon et al. This analysis included 63 randomized 
trials. The initial report from 1965-1993, showed a significant absolute 
overall survival benefit of 4%, both at 2 and 5 years (p<0·0001) in favour 
of chemotherapy.  
 
Concomitant chemotherapy showed an absolute survival benefit at 
2 and 5 years of 8%. In adjuvant setting, there wasn’t significant effect of 
chemotherapy seen on survival, and similar was the case for neoadjuvant 
trials. There was, nevertheless, a significant benefit with platinum plus 
fluorouracil (hazard ratio 0·88, 95% CI 0·79–0·97). The effect of 
multiagent concomitant chemotherapy was significantly greater than 
single-agent chemotherapy (hazard ratio 0·69 vs 0·87,p<0.01). For the 
effect of chemotherapy on survival by covariate values, the only 
significant observation was a decreasing effect of chemotherapy on 
survival with increasing age (trend test, p=0·05).As far as timing of 
chemotherapy is concerned, there was a non-significant decrease in risk 
of death in the concomitant chemotherapy group. This meta-analysis 
included trials which were very heterogeneous and no solid conclusion 
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could be drawn regarding the routine use of chemotherapy and the 
regimen to be used.38 
 
However, the update of this analysis, published in 2009. This 
included 93 randomized trials and demonstrated an overall absolute 
benefit of chemotherapy to be 6.5% at 5 years andthe hazard ratio was 
0.81 (p < 0.0001). Whereas  the absolute benefit of Induction 
Chemotherapy at 5yrs was 2.4% and that of Adjuvant Chemotherapy -
1.0+ 2.2 % .This absolute benefit in the meta analysis proves that 
Concomitant Chemotherapy as superior results and shows advantage over 
induction or adjuvant chemotherapy. 
 
There wasn’t significant difference in the benefit of chemotherapy 
on survival (p=0.14) between postoperative or curative radiotherapy with 
conventional or altered fractionation. Mono and poly-chemotherapy did 
not differ but the effect of chemotherapy was significantly higher (p = 
0.006) with platinum than with other types of mono-chemotherapy 
agents. There was only one negative “cisplatin alone” trial in this meta-
analysis which used a cumulative dose of 140 mg/m2 suggesting that the 
total dose of Cisplatin should be considered. It was also demonstrated that 
there is a statistically significant decreasing effect of chemotherapy on 
survival with increasing age.37 
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 This Meta-Analysis clearly states the benefit of concurrent Chemo 
radiotherapy in the squamous cell carcinoma of Head and Neck beyond 
any doubt. 
 
Latest trial Concurrent Vs InductionChemo: 
The DeCIDE, a phase III randomised trial using induction 
chemotherapy with Docetaxel, 5 fluorouracil and cisplatin in N2/N3 neck 
SCCHN(2012 ASCO meeting). Patients were randomised to chemo 
radiation alone with five days of docetaxel 25 mg/m2, 5 fluorouracil 600 
mg/m2 and hydroxyl urea 500 mg bid concurrently with radiation 150 
cGy bid or with two cycles ofinduction chemotherapy using docetaxel 75 
mg/m2, cisplatin 75 mg/m2 and 5 fluorouracil 750 mg/m2 for 5 days 
followed by the same chemo radiation. 280 patients were recruited to the 
study from 2004 to 2009 and the minimum follow up was two years. The 
primary end point was overall survival. From 142 patients randomized to 
induction, 91% received 2 cycles and 87% continued to chemoradiation. 
Grade 3-4 hematological toxicities were significantly higher in Induction 
Chemotherapy arm. The authors demonstrated that induction 
chemotherapy was associated with lower distant failure (DF) rates but an 
improvement in overall survival (OS) could not been validated. This was 
a negative study, as there was no overall survival difference with trends 
favoring the experimental arm in terms of disease-free survival.62 
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Another trial in ASCO 2012PARADIGM trial: with sequential 
chemoradiotherapy (induction chemo followed CCRT) versus concurrent 
chemoradiotherapy alone in locally advanced SCCHN : a randomised 
phase 3 trial-this study was conducted between 2004 to 2008, with a 
median follow up of 49 months 3-year overall survival was 73% in the 
induction therapy followed by chemoradiation group and 78%in the 
chemoradiation alone group (hazard ratio 1·09, p=0·77). Also, more 
patients had febrile neutropenia in the induction chemotherapy. Although 
survival results were shown to be good in both groups, there was no 
difference between those treated with induction chemotherapy followed 
by chemoradiation and those who received chemoradiation alone.  
 
Both the DeCIDE and PARADIGM trial failed to show a 
significant survival benefit with induction chemotherapy, but the toxicity 
were high in the induction arm; The option of induction Chemotherapy 
followed  by chemoradiation still can be considered in selected patients. 
 
PLATINUM BASED CHEMORADIATION: 
Concurrent chemoradiation with cisplatin as become the standard 
of care with the standard land mark trials. Cisplatin acts as a 
radiosensitizer increases efficacy of radiation even at low doses. 
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WEEKLY CISPLATIN Vs THREE WEEKLY CISPLATIN: 
Due to the benefit and effectiveness of Inj.Cisplatin concurrently 
with radiation in Squamous cell carcinoma of the Head and neck , it is 
used widely in the dose of 100mg/m2 day 1,22,43 regimen. This regimen 
as become the standard following many trials. But there are trials with 
smaller doses of Cisplatin which has proved to be quite effective. Though 
we are lack of the trials with direct comparison with low dose weekly 
Cisplatin and standard three weekly regimen; These nonstandard 
Cisplatin schedules have been preferred due to two main reasons – firstly, 
more frequent dosing may provide more radiosensitization during long 
course of radiation, and secondly, a smaller drug dose may have lesser 
chemotherapy related toxicity. With the three weekly regimen it was 
found that compliance to the schedule became a major issue, which is 
avoided in the case of  smaller weekly doses. Based on trials like the 
Intergroup and RTOG – 0129, it has been suggested that the cumulative 
threshold dose of Cisplatin to achieve maximal benefit is 200 mg/m2. 
Also, as discussed in the MACH-NC analysis, a dose below 140 mg/m2 
was found to have inferior results. 
 
WEEKLY CISPLATIN TRIALS: 
 A study published from TATA Memorial Hospital, Mumbai, by 
Tejpal Gupta in 2009, compared high dose concurrent Cisplatin with 
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weekly Cisplatin  30 mg/m2 with radiation dose of 70Gy. Planned was 
seven cycles of weekly Cisplatin, 65% of patients in the study received 
more than 85% of planned Cisplatin dose. With a mean follow-up of 19 
months, the 5-year local control was 57%, loco-regional control was 46% 
and the disease free survival was 43% respectively.29% cases hadgrade 3 
or higher acute mucositis and dermatitis in 35% cases respectively. This 
essentially manifested in patients receiving radiation dose ≥66 Gy and 6 
or more cycles of chemotherapy.The conclusion drawn from the study 
was weekly cisplatin has moderate efficacy with acceptable toxicity. In 
country like ours where there are limited resources weekly cisplatin as the 
potential to become an optimal chemotherapeutic regimen64. 
 
 Another study published by Homma et al in 2011, including 53 
patients with locally advanced squamous cell carcinoma used weekly 
cisplatin 40 mg/m2 on 7 weeks along with radiation of 70 Gy/2Gy per 
fraction in 35 fractions. The overall survival rate was 93.7% and disease 
free survival was 88%. The toxicity was manageable in all patients. The 
study demonstrated complete response rate of 98.1%.This study showed 
that weekly cisplatin is a feasible alternative with less toxicity without 
compromising the results. Major benefit is that the patients can be 
monitored frequently and dose adjustments can be made if required.65 
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Study published by Ho and his colleagues in 2008 compared the 
differences in dose intensity,  treatment delay, and toxicity between 
concurrent three weekly (80–100 mg/m2) and weekly (40 mg/m2) 
Cisplatin based chemo radiation in advanced head and neck. Most of the 
patients in weekly Cisplatin arm received a higher cumulative dose of 
240 mg/m2 or more as compared to the standard three weekly Cisplatin 
arm (p = 0.04). They also found that the three weekly regimen was 
associated with more delays (41% vs 29%) and omissions of 
chemotherapy (17.4% vs 5.6%) causing minimum number of patients to 
achieve a less cumulative cisplatin dose, potentially lowering dose-
intensity.66 
 
A similar study was conducted at the University of Florida, 
presented at the ASTRO 2009 meet, later published in Cancer J 2010. 
This study demonstrated that weekly Cisplatin 30 mg/m2 decreases the 
treatment toxicity without sacrificing efficacy in patients treated with 
concomitant chemo-radiation for locally advanced head and neck 
squamous cell carcinoma. 79% patients in the study were able to 
complete at least 6 cycles of chemotherapy and 95% patients received RT 
up to at least 72 Gy. The 5-year actuarial outcomes in this study were as 
follows: Loco regional control rate of 79%; Distant metastases, 12%; and 
overall survival of 59%. It was claimed by the authors that the toxicity 
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rates of the study were lower than those reported for RTOG 9914 and 
0129.67 
The Basket University experience in weekly cisplatin concurrent 
with radiation was presented in conjunction with 2011 ASCO annual 
meeting presented by F Kose et al. A retrospective analysis of 53 eligible 
patients treated in the year 2007-2009 showed that there is no significant 
difference in median overall survival in weekly Cisplatin and three 
weekly cisplatin groups. The loco regional control and distant relapses 
were also similar in both groups. The conclusion of the study was 
concurrent chemo radiotherapy with weekly cisplatin is as effective as 
three weekly cisplatin with very high bolus dose.68 
 
At University of Wisconsin, Tray nor et al studied the feasibility 
of weekly cisplatin with IMRT in locally advanced head and neck cancer. 
This study was conducted during a period of November 2001 to May 
2007. A total of 57 patients were included and a weekly cisplatin dose of 
30 mg/ m2 was used. The prescription dose to the GTV was 70 Gy. The 
loco regional control was 85.5 % and median overall survival was 86.9%. 
The conclusion drawn from the study was weekly cisplatin 30 mg/m2 
along with IMRT with a GTV dose of 70 Gy is well tolerated.69 
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The landmark reviews and meta-analysis in the literature have not 
shown the inferiority of combination chemotherapy with radiotherapy in 
head and neck cancer. Trials have been done using Cisplatin with other 
agents like paclitaxel, in order explore more avenues for better outcome 
in head and neck cancer. Since 5-fluorouracil has proven to be the best 
combination drug with Cisplatin for the cancer of the head and neck  by 
far in full dose regimens, this trial is conducted with Capecitabine 
Prodrug of 5-Fluorouracil,to prove its efficacy in locally advanced head 
and neck cancer. 
 
TRIALS WITH CISPLATIN AND CAPECITABINE IN HEAD 
AND NECK CANCER: 
 
 Oral Capecitabine, prodrug of 5Fluorouracil, is used in solid 
tumors like oesophagus, stomach, pancreas, colorectum and its role in 
recurrent head and neck cancer is well established. The role in concurrent 
chemoradiation with Cisplatin/carboplatin is emerging in the 21st century.  
 
 Phase I study by University of Virginia conducted by 
Christopher et al, U.S.A to determine the maximum tolerated dose of 
Capecitabine given Concurrently with Carboplatin and Radiation. This 
study included eleven patients  treated with Induction chemotherapy of  
carboplatin (AUC=2) in 6 weekly and Capecitabine up to 1,750 mg/m2 
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given orally or per gastric tube in divided doses on days 1-14 and 22-36. 
After a one-week break in the absence of progression, the patients 
received a second weekly chemotherapy 6 cycles and concomitant IMRT 
dose of 70Gy.  The Capecitabine dose was studied in different schedule. 
This study proved the MTD for Capecitabine at 850 mg/m2/day. Other 
grade 3 or 4 adverse effects, were due to the additive effects of radiation 
which did not meet DLT parameters: grade 3 mucositis and dysphagia                            
(4 patients), local pain (3 patients), radiation dermatitis (2 patients), and 
fatigue (3 patients).The relatively low dose of Capecitabine given during 
IMRT, the rate of locoregional control in this study was excellent. 
 
This trial concluded that the maximum tolerated dose of 
Capecitabine used Concurrently with Radiation is 850mg/m2/day. The 
combination of Capecitabine and carboplatin has shown effective against 
HNSCC and the response rate was similar to that of Capecitabine and 
cisplatin.70 
 
Another study by Andrew J. Sykes et al, this is Phase 1 study to 
establish the advantages of Capecitabine as a synchronous 
chemoradiotherapy agent in patients with Head and neck cancer. 
Capecitabine was given continuously throughout a week in bid dose 
starting at 350 mg/m2 bid. Radiotherapy dose was 55 Gy in 20 fractions 
56 
 
over 4 weeks. Capecitabine was given all days continuously with 
radiation without a break. A total of 24 patients were treated, out of 
which two patients developed DLT (grade IV mucositis) was reached at a 
Capecitabine dose of 550 mg/m2 bid. So they reclined the dose to 
500mg/m2bid.Radiotherapy was completed without delay in all cases. 
Median follow up is 21 months. Complete clinical responses were seen in 
all cases. 2yr disease free survival is 83%.Four patients developed 
recurrence. This study concludes that Capecitabine can be given 
continuously with radiation without one week gap at a dose of 500mg/m2 
bid.52 
  
Phase II study done by Jegannathen et al in 2011,to explore the 
efficacy of concurrent Oral Capecitabine with accelerated 
hypofractionated radical radiotherapy in locally advanced head and neck 
squamous cell carcinoma. 50 patients with stage III/IV SCCHN, of 
ECOG 0 to 2 were enrolled in this study during 2001-2004. The 
Capecitabine was given continuously at a dose was between 450 and 
550mg/m 2 twice daily, for 28 days. The radiotherapy dose was 55Gy in 
20 fractions/4 weeks, IMRT was not used. The complete response 
rate(CR), toxicity, locoregional control, overall survival(OS),disease-free 
survival(DFS) and cancer-specific survival was evaluated. The median 
age in this study was 55years; stage IV disease was 72%. After a median 
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follow-up of 6 years on the 30 surviving patients, 82% of patients 
completed the course of Capecitabine and 94% completed prescribed 
radiotherapy. Drug-related grade 3/4 acute toxicity (skin, bowel) was 
seen in 5 patients; grade 3 mucositis in 47patients. There weren’t any 
treatment-related deaths, renal toxicity grade 3/4 haematological toxicity. 
At the end of 3 months CR was attained in 90% of patients. Relapse 
occurred in 34% of patients by 5 years. At 3yrs, locoregional control was 
78%, overall survival 72%, cancer-specific survival 82% and DFS 62% 
and at 5 years were 72, 64, 75 and 56%, respectively. This schedule of 
synchronous Capecitabine for locally advanced SCCHN is well 
tolerated.71 
 
As the immediate local control in this series as complete response 
was 90% and locoregional control at 3yrs and 5yrs was 78% and 72%, it 
was concluded that oral Capecitabine as a single agent targeted therapy 
given with each fraction of radiation as superior results comparable to 
other drug regimens like 3 weekly Cisplatin. 
 
Study published bySherif A. Raafat et al done in Cairo 
University Egypt, comparing the efficiency of concurrent  Cisplatin 
versus oral Capecitabine with radical radiotherapy in locally advanced 
squamous cell carcinoma of the head and neck. Study was done during 
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2007-2009, 60 patients with stage III/IV head and neck cancer, ECOG 0 
to 1 were enrolled in this study. 30 patients were given cisplatin 30mg/m2 
IV infusion weekly for 6 weeks with conventional radiotherapy. The 
remaining 30 cases were given oral capecitabine 500 mg/m2bid, 
continuously for 28 - 35 days with conventional radiotherapy also. 
Radiotherapy dose was 66Gy in 2 Gy per fraction.73% of patients 
completed the entire course of Capecitabine and 80% completed 
prescribed Cisplatin. There were no treatment-related deaths or dose 
limiting toxicity. The complete response rate at 3 months was 77% in the 
Capecitabine group and 60% in the Cisplatin group. Relapse occurred in 
10/30 (33%) patients after 2 years in the Capecitabine group and in 12/30 
(40%) in the Cisplatin group. The median follow up period was 35 
months for overall survival and 33 for disease free survival. The overall 
survival and disease-free survival rates at 2 years were 67%, and 85%, 
respectively for the Capecitabine group versus 60% and 73% for the 
Cisplatin group.  
 
This study proved Synchronous chemoradiotherapy with 
Capecitabine was found to be very effective, with excellent response, 
local control and 3-year cancer-specific survival rates compared to the 
standard chemotherapy Cisplatin. 
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The complete response achieved with only Capecitabine as proved 
to be so effective that it can be given as a monotherapy in locally 
advanced head and neck squamous cell carcinoma.72 
 
A study comparing the benefits of concurrent Capecitabine and 
Cisplatin versus concurrent cisplatin and 5-flurouracil in locally advanced 
SCCHN by Seema Gupta et al, King George University Lucknow, 
2013. This study aimed to assess the efficacy and safety of both regimens 
in locally advanced squamous cell carcinoma of the head and neck. Out 
of 153 patients, with stage III or IV unresectable disease with no distant 
metastases and who had received two cycles of Taxol and cisplatin 
chemotherapy were randomly assigned to receive either concurrent 
cisplatin (75 mg/m2 in day 1 and 2) or 5-FU (750mg/m2 in D1-3 ) from 
the first day of radiotherapy at an interval of  21 days (Arm I) or cisplatin 
(75 mg/m2 in day 1 and 2) and Capecitabine(750 mg/m2 in two divided 
doses from day 1-14)from the first day of radiotherapy at an interval of 
21 days (Arm II). The Radiotherapy dose was 66 -70Gy in 2Gy per 
fraction, 5 days in a week. If grade 3 or 4 Capecitabine/5-FU-related 
hematological or non-hematological toxicity such as mucositis, diarrhea, 
and hand-foot syndrome developed, Capecitabine/5-FU was discontinued 
until the toxicity resolves. Subsequently the Capecitabine doses was 
reduced by 20%, doses of 5-FU was reduced by 20-25%. The dose of 
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cisplatin was also reduced to 50% if the patient’s creatinine clearance 
level was 30-50 mL/min. Cisplatin was withheld if the creatinine 
clearance level was less than 30 mL/min. If severe myelosuppression and 
febrile neutropenia develops CCRT was suspended for 1 week or 
interrupted. Results were Arm I, Complete response was 53.7% and 
Partial Response 41.8% while in Arm II Complete Response was 77.5% 
and Partial Response 16.9%. There were 56.7% primary and metastatic 
lymph node Complete Response and Partial Response 53.7% in Arm I 
while in Arm II there were primary and metastatic lymph node Complete 
Response 77.5% and Partial Response 78.9%. The quality of life among 
patients in this study, improved in Arm II because Cisplatin and 
Capecitabine as less complications and reduced hospital stay.73 
 
 These results showed that patients with Cisplatin and Capecitabine 
had a significantly better rate of complete response, fewer nodes, and 
better overall response compared to Cisplatin and 5FU patients. The two 
groups had a similar 3-year disease-free survival, progression free 
survival, and overall survival significantly. The quality of life also 
improved in patients with cisplatin and Capecitabine.  
 
 Study published in British journal of cancer in 2005, by JG Kim 
et al, to determine the efficacy and safety of concurrent 
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chemoradiotherapy with Capecitabine and cisplatin in patients with 
locally advanced SCCHN. This study enrolled 37 patients with 
unresectable locally advanced head and neck cancer. The chemotherapy 
schedule of two cycles of intravenous cisplatin of 80 mg/m2 on day 1 and 
oral Capecitabine 825 mg/m2bid from day 1- 14every 21 days. The 
radiotherapy dose was 70Gy in 2Gy per fraction, 5 days per week was 
delivered to the primary tumour site and neck. The primary tumour sites 
were oral cavity 6patients, oropharynx 11 patients, hypopharynx 8 
patients, larynx 3, nasopharynx 6, and paranasal sinus 3. After the 
chemoradiotherapy, CR was attained in 78.4% and partial responses in 
16.2% patients. Grade 3 or 4 neutropenia occurred only in two patients, 
grade 3 febrile neutropenia was observed only in one patient. After a 
median follow-up duration of one and half years, the estimated overall 
survival and progression-free survival rate at 2-year was 76.8 and 57.9%, 
respectively. Concurrent chemoradiotherapy with Capecitabine and 
cisplatin was found to be well tolerated and effective in patients with 
locally advanced SCCHN provides very good complete response and 
overall survival.74 
 
 All these trials prove that Cisplatin and Capecitabine concurrently 
with radiation is a better regimen compared to Cisplatin and 5 
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Fluorouracil with increased complete response, locoregional control and 
overall survival with less toxicity. 
 
  Also there are trials that use Capecitabine, carboplatin with Taxol 
in the induction chemotherapy followed by concurrent chemoradiation 
with same in view of organ preservation in advanced, unresectable head 
and neck squamous cell carcinoma.  
 
This trial was presented in ASCO 2010, it is a phase II study 
published by D. F. Saragiotto et al with patients who had biopsy proven 
stage III or IV SCC and no distant metastasis, PS 0 or 1, good organ 
function received two cycles of chemotherapy (CT) with i.v.Docetaxel 70 
mg/m2 on day 1 plus i.v. carboplatin AUC 5 on day 1 plus Capecitabine 
1g/m2 orally daily bid every 28 days. Patients with disease progression or 
stable disease were excluded. Responding pts received two more cycles 
of the same CT concurrent with concomitant boost radiation therapy (72 
Gy). The results 25patients enrolled in this study : 15 oropharynx, 8 
larynx and 2 hypopharynx. All pts completed the Induction 
Chemotherapy and Concurrent radiotherapy. The response rate was 88% 
and only one patient had progression after 3 months of treatment 
completion. During Concurrent chemoradiotherapy, the rate of grade 3 
febrile neutropenia was 36% and grade 3/4 mucositis was 72%. One 
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patient died during treatment as a result of a ruptured aortic aneurysm. 4.6 
years of median follow up showed only one patient died as a result of 
metastatic disease.75 
 
 Three-drug induction therapy with Docetaxel, Carboplatin and 
Capecitabine 1g/m2 followed by concurrent by the same agents and 
concomitant boost radiation therapy is feasible and very promising in a 
selected head and neck patient population, with high response and organ 
preservation rates. 
 
The Capecitabine was also used in recurrent and metastatic 
squamous cell carcinoma in head and neck after platinum based 
treatment. A study by Martinez et al, this study included patients with 
recurrent head and neck after concurrent chemoradiation with platinum 
based regimen. This study included 40 patients all patients had 
Capecitabine 1250mg/m2 bid,D1-14, every 21 days; all patients received 
four cycles. Overall response rate was 24.2%. PFS and OS were 4.8 and 
7.3 months, respectively. Hematological toxicitygrade3/4 were reported 
in six patients. Other toxicity were palmar-plantar erythroplasia(10%), 
mucositis (10%), dysphagia (10%) and diarrhoea (7.5%).79 
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This study proved the efficacy of Capecitabine in recurrent head 
and neck squamous cell carcinoma. But Capecitabine is used mostly in 
curative concurrent chemoradiation in most of the trials. 
 
Although all the land mark trials show Cisplatin and 5 fluorouracil 
has the standard combination with radiation; the toxicity with 5FU such 
as mucositis, diarrhea which is increased along with radiation causes 
increased hospitalization and treat breaks. Capecitabine prodrug of 5-FU 
as equal efficacy and reduces the toxicity produced by 5-FU. Also 
Capecitabine is a oral drug increases patient compliance to the treatment.    
 
 The reason for combining cisplatin and capecitabine with radiation 
in this present study are mainly because of the mechanism of interaction 
of the two drugs. 
 
Mechanism of interaction: Cellular hypoxia, cell cycle age distribution, 
intrinsic radio sensitivity of the tumour are important factors that 
determine the sensitivity of the tumour to radiation. 
 
HYPOXIA: 
Radiation kills the cancer cells by generating reactive hydroxyl free 
radical with the cellular water. In the presence of oxygen, the reactive 
free radical will react with the DNA strand, resulting in permanent DNA 
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damage. Oxygen will supply electron to the damaged DNA strand and 
destabilize the strand break. This enhancement effect of oxygen in 
radiation therapy is known as oxygen enhancement ratio. Without the 
electron supply from oxygen under hypoxic condition, the DNA damages 
induced by radiation could be repaired by the cancer cells. Chronic 
hypoxia will lead to amplification of certain oncogenes like ras, c- myc, 
c-raf-1 which are responsible for increased resistance to radiation. Also 
the radiation generates oxygen free radicals which damages DNA. It is 
also postulated that due to hypoxia chemotherapy drug diffusion distance 
is increased. This causes decreased amount of chemotherapy drug to enter 
the actively dividing tumor cells.76 
 
Thus by combining radiation with a chemotherapeutic drug which 
is active against hypoxic cells, we can overcome this resistance to 
radiation. Cisplatin is active against hypoxic cells. In Capecitabine 
metabolism, the main key enzyme Thymidine phosphorylase expression 
is increased in hypoxic conditions. 
 
Cisplatin alkylates the DNA and causesintrastrand and interstrand 
breaks, thereby makes it more vulnerable to radiation. It not only 
increases the damage caused by radiation but also inhibit repair of the 
radiation damage. Cisplatin inhibits the repair of sub lethal damage(SLD) 
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and potentially lethal damage (PLD). It also causes inhibition of cell 
repopulation and modification of the slope of dose response curve. 
 
The sensitivity to radiation varies widely depending upon which 
phase of the cell cycle, the cell lies. The G2 and M phase are three times 
more sensitive to radiation than S phase. The most radio resistant phase is 
S phase followed by early G1 phase. The exact mechanism for this is not 
known. This mechanism is exploited therapeutically in concurrent chemo 
radiation strategies. Most of the chemotherapeutic agents kill 
proliferating cells which are situated in the well oxygenated area. These 
areas lies close to capillaries hence they are easily accessible to 
chemotherapeutic agents. When these proliferative cells are killed, the 
bulk of the tumour is decreased and the interstitial pressure falls. This 
result in opening of closed capillaries and previously hypoxic cells 
become oxygenated. Since the tumour shrinks, the previously hypoxic 
areas move nearer to capillaries. Finally the loss of oxygenated cells 
results in more availability of oxygen to previously hypoxic cells which 
become oxygenated and susceptible to radiation. Tumour cells have 
accelerated cell proliferation, hypoxia and acidity which are not present 
in normal cells. Also the expression of the enzyme thymidine 
phosphorylase is increased in conditions with hypoxia, poor perfusion 
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and acidosis. This is the condition in most of the solid tumours mainly 
head and neck cancer. 
 
Due to the preferential activation the enzyme thymidine 
phosphorylase, Capecitabine concentration inside the tumour cell is 
higher compared to the normal tissues. Also the concentration of 
Capecitabine is higher than that of infusional 5FU, Capecitabine 
treatment leads to 2.9 times higher concentration of 5 FU in the tumour 
cell compared to non-malignant tissues.45, 50 
 
Thus concurrent chemoradiation with Cisplatin and Capecitabine is 
a better regimen compared to Cisplatin and 5 Fluorouracil. Also has 
previously described weekly Cisplatin is preferred than three weekly 
cisplatin because of less toxicity, patient compliance to the treatment 
without breaks. If the cumulative dose of weekly cisplatin reaches > 
200mg/m2, it has same efficacy compared the three weekly dose 
100mg/m2. Also with trials described Capecitabine can be used 
continuously with radiation in low dose of 500mg/m2 twice daily. 
 
This regimen of weekly cisplatin and daily Capecitabine has been 
tried in squamous cell carcinoma cervix also, shown better results.77 
Based on above studies the present study was formulated and done 
in our department. 
  
 
AIM & OBJECTIVES 
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AIM & OBJECTIVES 
 
The aim of this study was to evaluate the use of Capecitabine and 
weekly Cisplatin concurrently with conventional radiation in locally 
advanced squamous cell carcinoma of head and neck. 
 
Primary Objective:  
 To assess the immediate loco regional response rates in locally 
advanced squamous cell carcinomas of the head and neck treated with 
Capecitabine and weekly cisplatin concurrently with conventional 
radiation. 
 
Secondary Objective:  
 To assess the acute toxicity to the treatment concurrent 
chemoradiation with Capecitabine and weekly cisplatin. 
  
  
  
 
MATERIALS 
AND 
METHODS 
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MATERIALS AND METHODS 
STUDY DESIGN: 
This was a Single arm prospective study with a Phase II design. 
 
STUDY DURATION: March, 2014– August, 2014 
 
STUDY CENTRE: 
Department of Radiotherapy, Barnard Institute of Radiology & 
Oncology, Madras Medical college, Chennai. 
 
SAMPLE SIZE:  
30 consecutive patients with histopathologically proven squamous 
cell carcinoma of head and neck who fulfilled the inclusion criteria were 
recruited in the study from the outpatient department.  
 
The intent of treatment was to be radical, aiming for cure, 
considering their disease stage, co- morbidities and performance status. 
 
ETHICAL COMMITTEE APPROVAL: Approval from the institute 
ethical committee was obtained on 11.03.2014. 
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INFORMED PATIENT CONSENT:  
All patients enrolled in the study were informed about the merits 
and demerits of participating in this study and signed an informed consent 
form in their regional language, which is Tamil. 
 
INCLUSION CRITERIA: 
 Biopsy proven newly diagnosed squamous cell carcinoma of the 
head & neck. 
 Primary tumor sites: oral cavity, oropharynx, hypopharynx, larynx.  
 Age 20 - 70 years. 
 Stage III or IV, non-metastatic locally advanced head and neck 
squamous cell carcinoma. 
 ECOG 0-2. 
 No major life threatening comorbidities. 
 
EXCLUSION CRITERIA: 
 Patient who did not consent for chemoradiation at any point of time 
during treatment.  
 Patients with history of any malignancy previously and received 
treatment for the same. 
 Recurrent tumors. 
 Tumors of nasal cavity, paranasal sinuses and nasopharynx.  
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 Non Squamous Histopathology  
 Abnormal hepatic function, renal function, bone marrow reserve.  
 Patients with uncontrolled co morbid conditions like diabetes, 
hypertension. 
 Pregnant females. 
 
PRE TREATMENT WORK UP: 
1. Detailed history elucidation. 
2. Complete physical examination by inspection, palpation. 
3. Upper aerodigestive tract evaluation by direct and indirect 
laryngoscopy, anterior and posterior rhinoscopy and endoscopy if 
indicated to know the extent of disease and rule out a second primary. 
4. Biopsy from the primary tumor or fine needle aspiration cytology from 
the metastatic lymph node. 
5. Blood grouping and typing. 
6. Complete blood count. 
7. Renal function test. 
8. Liver function test. 
9. CT scan of the head and neck, plain and contrast, before initiating 
treatment and also after treatment for response assessment. 
10. Chest X ray postero-anterior view.  
72 
 
11. Cardiac evaluation and fitness.  
12. Naso-gastric tube insertion if indicated  
13. Dental prohylaxis including scaling, dental filling and extraction if 
required.  
14. Tumour stage, performance status and weight were recorded. 
Staging was done based on American Joint Committee staging manual 7th 
edition (for head and neck cancers). 
15. Weekly CBC, RFT, LFT before each cycle of chemotherapy. 
 
PATIENT PREPARATION DURING TREATMENT: 
All patients enrolled in the study were distributed pamphlets 
describing in brief the do’s and don’ts while on treatment and later.  
 
Quitting alcohol and tobacco  
The harmful effects of tobacco, both in smoking and nonsmoking 
form, and alcohol were explained to the patient and draw backs of its 
addictions  to treatment was explained. These addictions has inferior 
outcome after treatment and has increased risk of second malignancy due 
to field cancerization effect. 
 
Dental health: 
Chemoradiotherapy to oral cavity poses an increased risk of dental 
caries. As the production of saliva is altered both in quality and quantity 
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by concurrent chemoradiotherapy which leads to alteration of normal 
flora. Thus causes increased risk of caries formation due to mucositis and 
dryness. Oral discomfort due to mucositis can lead to decrease in 
brushing and flossing, also increases the risk of dental caries, which may 
lead to extraction, soft tissue necrosis, bone exposure, and 
osteoradionecrosis. 
 
Dental care  
Prior to irradiation all patients underwent dental evaluation; scaling 
and filling. Non-salvageable teeth were extracted prior to radiotherapy to 
reduce the risk of osteoradionecrosis. A gap of two weeks was given after 
dental prophylaxis for proper healing of gums. Prophylactic antibiotic 
treatment was started following extractions if necessary.    
 
Edentulous patients were evaluated for their oral hygiene any retained 
root tips. 
 
Patients were advised not to wear dentures until the mucosa is healed 
from the effects of radiotherapy. 
 
Patients were advised to use soft brush and fluoride containing 
toothpaste daily during and after radiotherapy. 
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Mucositis 
The major side effect of chemoradiotherapy is mucositis, a 
condition where patient perceives pain due to inflammation and 
ulceration of the mucosa. It occurs mainly due to disruption of normal 
mucosal barrier by chemoradiotherapy causes production of Reactive 
Oxygen Species resulting in increased production proinflammatory 
cytokines (IL-1β, IL-6) which causes tissue injury and apoptosis of cells 
in the mucosa. 
 
Retrospective review of over 200 head and neck cancer patients 
treated with radiotherapy at MD Anderson cancer centre, 66% of the 
patients had either grade 3 or 4 mucositis. According to various studies 
patients with oral cavity, nasopharynx, oropharynx cancer treated with 
concurrent chemotherapy or altered fractionation radiotherapy, had a 
higher rate of mucositis producing intense pain, weight loss, and 
treatment breaks which compromises loco regional control.  
 
 Studies shown that daily dose, cumulative dose and volume of 
irradiated tissue determine the severity of mucositis. This pain produced 
by mucositis can lead to nutrition compromise thereby lack of proper 
hydration and oral hygiene. The desquamated epithelium, fibrin, and 
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polymorphonuclear leukocytes in a moist background provide a favorable 
environment for opportunistic infections such as candidiasis.  
 
Thus in this study patient were suggested following oral measures 
to improve their oral hygiene during radiation. 
 
- Patients oral health were monitored daily during treatment. 
- All patients were advised to gargle 20 to 25 mL of indigenously 
prepared mouthwash by dissolving three teaspoons of soda 
bicarbonate and three teaspoons of table salt (sodium chloride) in 
200ml of distilled water, for every 4 to 6 hours.  
- Morphine sulfate mouthwash was used as an alternative to produce 
pain relief .Alcohol free commercial mouth wash was also used.  
- Patients who developed mucositis were managed in addition with 
antibiotics and low dose corticosteroids. Oral candidiasis was 
treated with tablet Fluconazole 150 mg per oral for 7 days. 
 
Other precaution: 
Patients advised to restrain coarse and hot food items as they serve 
as irritant and exacerbate mucositis. 
Oral physiotherapy - in the form of mouth stretching and mouth 
opening exercise also advised to patients to avoid trismus. 
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NUTRITIONAL CARE: 
Most of the Head and neck cancer patients suffer from dysphagia 
and odynophagia either because of the tumor or due to treatment related 
effects like mucositis. This can affect the quality of life results in 
decreased food intake and they become nutritionally deprived resulting in 
weight loss. 
 
All patients enrolled in this study were given dietary advice and 
encouraged to take easily available, nutritionally rich local foods, dairy 
products and fresh fruits and juices (avoid citrus fruits, acidic and spicy 
foods). Everyone encouraged to take supplemental calories before 
treatment daily two eggs and milk. 
 
Homemade preparation of health mix which is rich in protein, was 
suggested to regenerate tissue protein. Small soft meals, in the form of 
bland diet at room temperature was advised. Protein supplements were 
given to patients. All patients were monitored for weight loss every week 
and special meals were designed for individual patients. 
 
Mostly during third or fourth week of radiation patients develop 
severe mucositis. and need supplementary nutrition. Parenteral nutrition 
was also given if needed.Those patients who developed grade 3 or 4 
77 
 
dysphagia were treated with a naso-gastric tube insertion so that nutrition 
was not compromised.  
 
Before initiation of treatment, it was made sure that all patients had 
normal blood, renal and liver function tests and everyone had given 
written consent for the treatment. 
 
TREATMENT PROTOCOL: 
  30 locally advanced head and neck cancer patients were selected 
consecutively from the outpatient department, who then underwent the 
pre treatment work up as mentioned before. Following that they were 
treated with concurrent chemoradiation with Capecitabine and weekly 
Cisplatin and radiotherapy in a conventional fractionated manner.  
 
RADIATION THERAPY:  
All patients were treated with a conventional dose schedule of 2 Gy 
per fraction with a Theratron Phoenix Tele Cobalt-60 machine.  
 
Patient Position:  
Patients were made to lie in the supine position with neck slightly 
extended.  
 
Patient Immobilization:  
Strict immobilization was practiced while irradiating the patient.  
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Radiation Portals:  
Patients were treated with opposing lateral radiation portals. 
 
Verification:  
X-ray simulation was done with the patient in treatment position to 
verify the treatment field.  
 
Radiation Dose:  
Patients were treated with a dose of 2 Gy per fraction, with 5 
fractions per week, up to a total dose of 66Gy. Aim was to complete 
radiation within 6.5 weeks. Appropriate shielding was done to limit the 
spinal cord dose to 40 Gy as per the institutional policy.  
 
Dose constraints:  
Following were considered:  
- Tolerance dose of spinal cord- 45 Gy in conventional fractionation for  
5 to 10 cm.  
-Parotid - up to 26 Gy after which permanent xerostomia is expected to 
occur. 
  
CHEMOTHERAPY SCHEDULE:      
 Inj.Cisplatin 40mg/m2 diluted in 500 ml normal saline,infused over 
2 hours, every week on Mondays, during radiationto a total of 6 - 7 cycles 
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in 6.5 weeks..Tab.Capecitabine 500mg/m2 twice daily, combination of 
500mg,150mg tablets throughout the period of irradiation. Intake of 
Capecitabine is not consistent with the timing of radiation. Renal and 
hematologic parameters were assessed prior to each cycle of 
chemotherapy. 
 
PREMEDICATION:  
All patients were pre hydrated with one pint of normal saline over 
one hour before starting chemotherapy.  
Premedication given 30 minutes prior to chemotherapy included the 
following:  
 Inj. Ondansetron 8 mg IV.  
 Inj. Dexamethasone 8mg IV.  
 Inj. Ranitidine 50 mg IV.  
 Inj. Chlorpheniramine 4mg IV.  
Injection Cisplatin 40mg/m2 mixed in 500 ml of normal saline and 
infused at 40 drops per minute in about 2 hours. Following this 500ml of 
normal saline was infused again over an hour. 
Blood investigations were repeated every week before 
chemotherapy and hemoglobin < 10g% was corrected by blood 
transfusion. Colony stimulating factor was given when the Absolute 
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Neutrophil Count fell below 1000 cells/cubic millimeter. Symptomatic 
thrombocytopenia was corrected by platelet transfusion. 
 
ASSESSMENT DURING CHEMORADIATION:  
Toxicity Assessment:  
Patients were reviewed every day before radiation for any acute 
toxic reactions and infections. Reactions like skin desquamation, 
mucositis, laryngitis, dysphagia etc. were recorded and graded based on 
RTOG acute radiation morbidity criteria. If a patient developed grade 3 or 
higher reactions chemoradiation was suspended. Careful attention was 
given for maintenance of hydration, adequate dietary intake and good oral 
hygiene.  
 
 Hematological and renal parameters were assessed on a weekly 
basis before every weekly dose of chemotherapy. As already described 
hematological parameters were assessed and treated. If renal parameters 
are raised adequate hydration was done and nephrologist opinion 
obtained. 
 
RESPONSE EVALUATION:  
All patients were reassessed by clinical examination and with a CT 
Neck, 6 weeks after completion of concurrent chemo radiation.  
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Response to treatment was described based on the Response 
Evaluation Criteria in Solid Tumors (RECIST 1.1 version) Criteria. 
 COMPLETE RESPONSE: Disappearance of all target lesions; 
malignant nodes <10 mm.  
 PARTIAL RESPONSE: At least 30% reduction in the sum of the 
longest diameter of target lesions, taking as reference the baseline 
study; confirmed at 4 weeks.  
 STABLE DISEASE: Neither partial response nor progressive 
disease criteria are met, in a minimum time set by the protocol.  
 PROGRESSIVE DISEASE: At least 20% increase in the sum of 
the diameter, with a minimum absolute increase of 5 mm, taking as 
reference the smallest sum in the study or appearance of new 
lesions.  
 
FOLLOW UP: 
 
 Patients after completion of concurrent chemoradiation were 
discharged from the hospital. Response evaluation was done based 
on RECIST criteria after 6 weeks.  
 Chest imaging, dental evaluations were done when indicated 
clinically. Continued smoking cessation, counseling to the patient 
and attender, rehabilitation, speech and swallowing therapy.  
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STATISTICAL ANALYSIS:  
The patient factors, tumor factors, response to treatment, and 
toxicities were thoroughly analyzed. The results are expressed in 
percentage. Since this  study is single armed one and also the sample size 
was only 30, the levels of significance cannot be commented on. 
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TREATMENT PROTOCOL 
Patient Selection  
Based on inclusion criteria 
 
 
Pretreatment evaluation including blood investigations, 
Imaging and Dental prophylaxis 
 
 
Treatment administration- concurrent chemoradiotherapy  
with Capecitabine and weekly Cisplatin 
 
Response assessment every week          and Regular monitoring of 
toxicities   
 
Treatment completion 
 
 
   
Review after 6 weeks for response assessment 
 
  
RESULTS 
AND 
ANALYSIS 
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RESULTS AND ANALYSIS 
The total 30 patients recruited completed their entire treatment protocol 
and all of them were available for analysis of results. 
PATIENT CHARACTERISTICS: 
AGE DISTRIBUTION: 
 43% of the patients belonged to the age group 51- 60yrs, followed 
by 41 -50yrs. The mean age of presentation was 55.5yrs. The youngest 
patient age was 35yrs and the oldest was 64yrs.(figure no:3) 
Table no: 4, AGE DISTRIBUTION OF THE STUDY POPULATION 
 
 
 
 
AGE GROUP 
 
NUMBER 
 
PERCENTAGE 
 
31- 40yrs 
 
6 
 
20% 
 
41 -50yrs 
 
9 
 
30% 
 
51-60yrs 
 
13 
 
43% 
 
61-70yrs 
 
2 
 
7% 
  
Figure no:3,Age distribution of the study population  
 
 
 
Figure no: 4, Gender distribution of the study population  
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GENDER: 
The gender distribution in the study population is dominated by the 
exposure of risk factors tobacco, alcohol etc. Since male population are 
more frequent for exposure, this study as 24 male patients followed by 6 
female patients. (figure no :4). 
 
Table no: 5, GENDER DISTRIBUTION OF THE STUDY 
POPULATION 
 
SEX NO. OF PATIENTS PERCENTAGE 
MALE 24 80% 
FEMALE 6 20% 
 
PERFORMANCE STATUS:  
All patients in this study had a general performance status of 
ECOG (Eastern Cooperative Oncology Group)grade 0 or 1.(figure no:5) 
Table no:6, ECOG performance status 
ECOG NO.OF PATIENTS PERCENTAGE 
ECOG 0 18 60% 
ECOG 1 12 40% 
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HABITS: 
 
 In the natural history of head and neck cancer, habits /addictions of 
the patients to tobacco, alcohol plays a major role. In this study, as 
expected, majority of the patients had habit of both tobacco (smoking and 
smokeless) and alcohol  
 
Table no: 7, Habits / addictions in the study population. 
 
HABITS 
NO.OF 
PATIENTS 
PERCENTAGE 
TOBACCO(SMOKING) 19 63% 
TOBACCO(SMOKELESS) 11 36% 
ALCOHOL 16 53% 
NONE 4 13% 
 
SYMPTOMS AND SIGNS: 
 
 Among the study patients the most common presenting symptom 
was dysphagia followed by ulcer/growth.(figure no:6) 
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Table no: 8, Symptoms/Signs 
 
PRESENTING 
SYMPTOMS/SIGNS 
 
NUMBER 
 
PERCENTAGE 
PAIN 12 40% 
ULCER/GROWTH 16 53% 
DYSPHAGIA 18 60% 
ODYNOPHAGIA 12 40% 
NECK SWELLING 7 23% 
VOICE CHANGE 4 13% 
 
PRIMARY SITE: 
 
 In this study Oropharynx were 9 patients, followed by 
Hypopharynx 8 patients then Oral cavity 7 patients and larynx 6 
patients.(figure no:7) 
  
Figure no:5, ECOG performance status 
 
 
Figureno:6, Symptoms and signs 
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Table no:9, Primary site 
PRIMARY SITE NUMBER PERCENTAGE 
ORAL CAVITY 7 23.3% 
OROPHARYNX 9 30% 
HYPOPHARYNX 8 26.67% 
LARYNX 6 20% 
 
SUBSITE ANALYSIS: 
In the subsite anaylsis Tongue (antr 2/3 and posterior 1/3) are equal 
in number.(figure no: 8) 
Table no: 10, subsite analysis 
 
SUBSITE NUMBER PERCENTAGE 
TONGUE 6 20% 
POSTERIOR 1/3 
TONGUE 
6 20% 
RMT 1 3.33% 
TONSIL 3 10% 
POST CRICOID 3 10% 
PYRIFORM SINUS 5 16% 
SUPRAGLOTTIS 6 20% 
 
TUMOR STAGE: 
This study included only locally advanced head and neck cancer T 
stage with T2 (with node positive), T3, T4a .(figure no:9) 
Figure no:7, Site distribution of the study population 
 
 
 
Figureno:8,Subsite Analysis 
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Table no:11, Tumor stage  
T STAGE NUMBER PERCENTAGE 
T1 0 0 
T2 2 6% 
T3 16 53% 
T4 12 40% 
 
NODAL STAGE: 
 
 Nodal staging 60% of the patients as N2, only 3% (only one 
patient) had N3 disease.(figure no:10) 
 
 Table no: 12, Nodal stage 
NODAL STAGE NUMBER PERCENTAGE 
N0 2 6% 
N1 9 30% 
N2 18 60% 
N3 1 3% 
 
Figure no: 9, T stage in the study population 
 
 
 
Figureno:10,Nodal stage in the study population 
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STAGE GROUPING OF THE STUDY SAMPLE: 
 
 The staging grouping was done according to AJCC 7th edition. 
As our general population usually present late to the hospital most of our 
patients were in stage IV a and only one patient in stage IV b (T3N3M0). 
(figure no:11) 
 
Table no: 13, stage grouping 
 
STAGE GROUPING NUMBER PERCENTAGE 
STAGE III 7 23.33% 
STAGE IV A 22 73.33% 
STAGE IV B 1 3.33% 
 
HISTOLOGICAL DIFFERENTIATION: 
 
 Most of the patients in the study belonged to moderately 
differentiated histology followed by poorly differentiated. 
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TABLE NO:14, Histological differentiation 
HISTOLOGICAL 
DIFFERENTIATION 
NUMBER PERCENTAGE 
WELL 
DIFFERENTIATION 
7 23.33% 
MODERATELY 
DIFFERENTIATED 
17 56.66% 
POORLY 
DIFFERENTIATED 
6 20% 
 
 
TREATMENT RESULTS: 
  All 30 patients completed the treatment protocol and were 
assessed at the end of 4-6 weeks. The evaluation was done clinically, 
which included ENT (Ear, Nose, Throat) examination with indirect 
laryngoscopy and direct laryngoscopy, and CT imaging (plain and 
contrast). The RECIST 1.1 criteria were used to classify the response type 
into a complete response, partial response, static or progressive disease. 
 
 
 Figure no: 11, Stage grouping 
 
 
 
Figure no:12, Treatment results - Response 
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RESPONSE RESULTS: 
 
 In this study 73% of the patients had complete response and 27% 
had partial response. There was no static response or progression in the 
study. (figure no:12) 
 
Table no:15, Response results 
RESPONSE NUMBER PERCENTAGE 
COMPLETE 
RESPONSE 
22 73.33% 
PARTIAL 
PRESPONSE 
8 26.66% 
STATIC RESPONSE 0 0 
PROGRESSION 0 0 
 
SUBSET ANALYSIS:  
All the patient characteristics were analyzed for response at the end 
of the treatment. The results are stated in percentage. Due to the single 
arm analysis and small sample size of 30 patients, the study tests of 
significance cannot be relied on. 
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SITE Vs RESPONSE: 
In this study Oropharynx had highest complete response for 7 
patients, followed by larynx all 6 patients had complete response. Partial 
response was equal in both Hypopharynx and oral cavity.(figure no:13) 
 
Table no:16, Site Vs Response 
 
SITE 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
ORALCAVITY 4(57%) 3(42.85%) 
OROPHARYNX 7(77.8%) 2(22.2%) 
HYPOPHARYNX 5(62.5%) 3(37.5%) 
LARYNX 6(100%) 0 
 
TUMOR STAGE Vs RESPONSE: 
 Out of the 16 T3 lesions, 12 patients had complete response 
whereas out of the 12 T4a patients only 8 had complete response. This 
shows the advanced nature of the disease.(figure no: 14) 
 
 
Figure no:13, Site Vs Response 
 
 
 
Figure no:14, T stage Vs Response 
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Table no: 17, Tumor Stage Vs Response 
 
TUMOR 
STAGE 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
T1 0 0 
T2 2(6%) 0 
T3 12(40%) 4(13.34%) 
T4 8(26.67%) 4(13.34%) 
 
 
NODAL STAGE Vs RESPONSE: 
 
 All patients with N1, N2a, N2b nodes had complete response. Out 
of the 13 patients with N2c nodes 9 had complete response only 4 
patients had partial response.  Only one patient had N3 node with partial 
response.(figure no:15) 
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Table no:18, Nodal Stage Vs Response  
 
NODAL 
STAGE 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
NO 2(6.66%) 0 
N1 9(30%) 0 
N2a 2(6.66%) 0 
N2b 3(10%) 0 
N2c 10(33.33%) 3(10%) 
N3 0 1(3.33%) 
 
HISTOLOGICAL DIFFERENTIATION Vs RESPONSE: 
 
 As already mentioned maximum numbers of the patients in our 
study were moderately differentiated; in which 12 patients had complete 
response and 5 had partial response. All poorly differentiated cancer had 
complete response. Out of seven well differentiated tumors only 4 had 
complete, this is lower when compared to the other two differentiations. 
(Figure no:16) 
 
 
Figure no :15, Nodal stage vs Response 
 
 
Figure no: 16, Histologic differentiation Vs Response 
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Table no: 19, Histological differentiation Vs response. 
 
HISTOLOGIC 
DIFFERENTIATION 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
WELL DIFFERENTIATED 4(57.1%) 3(42.85%) 
MODERATELY 
DIFFERENTIATED 
12(70.58%) 5(29.41%) 
POORLY DIFFERENTIATED 6(100%) 0 
 
PERFORMANCE STATUS Vs RESPONSE: 
 The ECOG performance status among the study patients did not 
show much difference in the response rates, as the study patients are in 
the ECOG 0 OR 1. 
 
Table no: 20, ECOG Vs Response 
 
ECOG 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
0 13(43.33%) 5(16.66%) 
1 9(30%) 3(10%) 
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PRIMARY AND NODAL SITES – DIFFERENTIAL RESPONSE: 
 
 In this study the complete response rate in the primary site was 
73% whereas in that of the nodal region was 87%.(figure no:17,18) 
 
OTHER FACTORS AFFECTING RESPONSE: 
 
AGE: 
 In this study people aged less than 50yrs were 15 patients out of 
them 12(80%) had complete response. In case of above 50yrs there were 
15 patients, in which only 66% had complete response.  
 
Table no: 21, Age Vs Response 
 
AGE 
GROUP 
COMPLETE 
RESPONSE 
PARTIAL RESPONSE 
31-40Yrs 5(83.33%) 1(16.66%) 
41-50Yrs 7(77.77%) 2(22.22%) 
51-60Yrs 8(61.5%) 5(38.4%) 
61-70Yrs 2(100%) 0 
 
 
 
Figure no: 17, Response in the Primary  
 
Figure no:18, Response in the Nodes 
 
Figure no: 19, Treatment delay 
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GENDER Vs RESPONSE: 
As the male population dominated the study 75% of the males had 
complete response in contrast to 66% of the females. As the male and 
female ratio was not equivalent it cannot be considered as significant. 
 
STAGE Vs RESPONSE: 
 The complete response in Stage IV was 69% but the partial 
response was 30% which is high compared to Stage III partial response 
14%. This is due to the fact that Stage IV disease is infiltrative and 
extensively spreading. 
 
Table no :22, Stage Vs Response 
STAGE 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
STAGE III 6(86%) 1(14.2%) 
STAGE IV 16(69.5%) 7(30.4%) 
 
TREATMENT BREAK Vs RESPONSE: 
 
 Treatment delay due to toxicities which caused prolongation of 
overall treatment time was analyzed for response. There was treatment 
delay in 47% of the patients compared to 53% who proceeded without 
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delay in overall treatment time. Among the 47% of the patients, most of 
the patients had 1-3 days treatment break had 83% complete response 
whereas only 62.5% had complete in case of treatment break for 4 days or 
more.(figure no:19,20) 
 
 Though there was treatment break all patient chemoradiation. 
 
Table no: 23, Treatment break Vs Response 
TREATMENT 
BREAK 
NUMBER 
COMPLETE 
RESPONSE 
PARTIAL 
RESPONSE 
1-3 DAYS 6 5(83.33%) 1(16.67%) 
> 4DAYS 8 5(62.5%) 3(37.5%) 
 
TREATMENT RELATED ACUTE TOXICITIES: 
ACUTE LOCAL TOXICITY: 
 Acute local toxicity is done by RTOG Acute morbidity scoring 
criteria.(Table 20, figure no:21) 
 
SKIN REACTION: 
 
In this study 77% of the patients had Grade 1 skin reactions in the 
form of dry desquamation, decreased sweating. Another 16% had patchy 
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moist desquamation whereas only 6% of the patient had grade 3 confluent 
moist desquamation. 
 
MUCOSITIS: 
 As expected there was high incidence of mucositis in this study. 
Nearly 40% of the study population developed grade 2 reactions in the 
form patchy mucositis. Also 16% had grade 3 confluent mucositis but 
there was grade 4 mucositis in 6% of the patients which required 
treatment break and supportive measures with analgesics, strict oral 
hygiene, mouth wash with alcohol free antibacterial solution. 
Also Inj.Dexamethasone 8mg  i.v. bid was given for 4-5 days. 
 
SALIVARY GLAND /XEROSTOMIA: 
 
 The salivary gland toxicity in the form of xerostomia is usually 
managed with commercially available artificial salivary agents.73% of 
the patients had grade1 xerostomia with complaints like dry mouth and 
slightly altered taste sensation. Some 16% patients developed complete 
dryness, sticky saliva as grade 2 toxicity reaction. 
 
PHARYNGITIS: 
 The patients with grade 2 and grade 3 dysphagia were given Ryles 
tube feeding and adequate nutrition was maintained. If needed 
Figureno:20 Response Vs Treatment break 
 
 
 
Figure no: 21,Acute toxicity 
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intravenous fluids and parentral nutrition were given. Only 26% of the 
patients had grade 1 dysphagia remaining had either grade 2 or 3.  
 
LARYNGITIS: 
 Grade 2 Laryngitis developed in 46% of the patients who had 
hoarseness of voice and constant cough requiring cough syrup. Grade 3 
laryngitis developed in 26% of the patients they had only whispered 
speech. Remaing had grade 1 toxicity which subsided on its own. 
 
Table no:24, Acute toxicity 
 
ACUTE 
TOXICITY 
GRADE 
0 
GRADE 
1 
GRADE 
2 
GRADE 
3 
GRADE 
4 
GRADE 
5 
SKIN 
REACTIONS 
 
0 
23 
(76.66%) 
5 
(16.66%) 
2 
(6.66%) 
 
0 
 
0 
 
MUCOSITIS 
 
0 
11 
(36.66%) 
12 
(40%) 
5 
(16.67%) 
2 
(6.67%) 
 
0 
SALIVARY 
GLAND 
3 
(10%) 
22 
(73.3%) 
5 
(16.67%) 
 
0 
 
0 
 
0 
PHARYNGITIS/ 
DYSPHAGIA 
 
0 
8 
(26.67%) 
11 
(36.67%) 
11 
(36.67%) 
 
0 
 
0 
 
LARYNGITIS 
 
0 
8 
(26.67%) 
14 
(46.67%) 
8 
(26.67%) 
 
0 
 
0 
 
SYSTEMIC TOXICITY: 
 The treatment related systemic toxicity was assessed with CTCAE  
V 4.03 and presented (Table no: 21, figure no:22) 
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NAUSEA: 
 83% of the study population developed loss of appetite grade 1 
nausea during their treatment course.13% of the developed grade 2 
nausea. 
 
VOMITING: 
 80% of the patients had  grade 1(1 or 2 episode) of vomiting during 
chemotherapy mainly Cisplatin. Only 6% of the patients had grade 2(3 or 
4 episodes) of vomiting managed by Oral Rehydration Salt and 
Inj.Ondansetroniv bid for 3 -5 days. Intravenous fluids were given 
whenever necessary. 
 
DIARRHOEA: 
 Only 6% of the patients had grade 1 diarrhoea. Other than that 
none of the study patients had diarrhea. Mostly the grade 1 diarrhoea is 
self-limiting, anti-motility drugs like Tab. Loperamide was used when 
needed.  
 
HAND FOOT SYNDROME:  
  The dose limiting toxicity of Capacitabine hand foot syndrome did 
not occur in any patients in this study. 
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Table no: 25,Systemic toxicity 
TOXICITY GRADE 1 GRADE 2 GRADE 3 GRADE 4 
 
NAUSEA 
25 
(83.33%) 
4 
(13.33%) 
1 
(3.33%) 
0 
 
VOMITTING 
24 
(80%) 
6 
(20%) 
0 0 
 
DIAHORREA 
2 
(6.66%) 
0 0 0 
 
HEMATOLOGICAL TOXICITY: 
ANAEMIA: 
 In this study 18 patients had hemoglobin >11g % and 26% had 
reduction in their Hb levels during treatment between 9.5 -11g%. 13% of 
the patients developed reduction in Hb levels to below 9g% and required 
Packed cell transfusion.(figure no:23) 
 
Table no: 26, Anemia 
ANEMIA NUMBER PERCENTAGE 
GRADE 0 18 60% 
GRADE 1 8 26.67% 
GRADE 2 4 13.33% 
GRADE 3 0 0 
GRADE 4 0 0 
 
Figureno:22,Systemic toxicity 
 
 
 
Figure no: 23, Hematological Toxicity 
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LEUCOPENIA:  
 About 27 patients had WBC count >4000 during entire treatment. 
Only 3 patients developed reduction in WBC count level during 
chemotherapy between 3000 – 4000 grade1 Leucopenia. This can be 
attributed to the drug capectiabine. 
 
NEUTROPENIA: 
 There was no neutrophil count reduction in the study. 
 
THROMBOCYTOPENIA:  
 None of the study patients developed thrombocytopenia. 
 
RENAL TOXICITY: 
  All patients had normal renal function tests. Hence none of the 
patient developed renal toxicity. 
 
  
  
 
DISCUSSION 
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DISCUSSION 
The head and neck cancer census incidence is increasing in the 
present decade. Mainly in India, due to the habit and addiction towards 
tobacco in smoked form like cigarettes or beedi also in smokeless forms 
like pan, kurkhaetc plays a major causative effect. As the youngster’s 
exposure to these agents increase, there is rise in cancer incidence, mainly 
head and neck cancer. 
As the head and neck cancer affects the quality of life in patients 
due to disfigurement, dysphagia, hoarseness of voice etc. Patients in our 
country present in advanced stage due to lack of awareness, illiteracy, 
poor socioeconomic status. This gives them very limited treatment 
options. 
 Many trials have been published in different radiation and 
chemotherapy combinations in head and neck cancer. The standard of 
care is proved to be concurrent chemoradiation with radiation 66-70 Gy 
in 33 – 35 fractions in two Gy per fraction 5 days a week along with 
chemotherapy Inj. Cisplatin 100mg /m2 in D1, 22 and 43. 
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The drawback in this regimen is Cisplatin in high dose is not 
tolerated by most of the people and toxicity is high. Thus the dose of 
Cisplatin is given by split weekly low dose in many institution, this 
regimen as the same efficacy as the three weekly regimen with much less 
toxicity. MACHNC trial also states that the cumulative dose cisplatin 
should more than 200mg/m2. 
 
 Various concurrent chemoradiation trials as proven the benefit of 
weekly cisplatin single agent as equivalent results. Even a study done in 
our department Barnard institute of Radiology and Radiotherapy also 
showed that weekly cisplatin and three weekly cisplatin both  as similar 
treatment results except that the toxicity in weekly is much less compared 
to the three weekly regimen. 
 
Table no: 27 
CISPLATIN WITH 
RADIATION 
COMPLETE 
RESPONSE 
RATE IN % 
PARTIAL 
RESPONSE 
RATE IN % 
THREE WEEKLY 64 36 
WEEKLY 62 38 
 
 Thus single agent weekly cisplatin is an accepted regimen. 
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COMBINATION CHEMOTHERAPY: 
 
 Though MACHNC – Meta analysis of chemoradiation in head and 
neck cancer suggests that there is no added benefit with combination 
chemotherapy over single agent Cisplatin but toxicity as increased. But it 
also showed that combination of Cisplatin based regimens has better 
results than other single agent drugs. 
 
 Based on all these data combination of Cisplatin and 5 Fluorouracil 
has been widely used in locally advanced head and neck cancer along 
with radiation. 
 
The dose of Cisplatin and 5 FU used in this combination are 
100mg/m2 and 1000g/m2  continuous infusion for 5 days in the interval of 
21 days. The demerits of this combination are high mucositis and diarrhea 
produced by 5FU resulted in toxicity and treatment breaks. To overcome 
this toxicity a study done in a Korea institute tried weekly combination of 
Cisplatin and 5FU. In this study they used weekly Cisplatin 
20mg/m2along with 5FU 750mg/m2,concurrently with radiation dose of 
70Gy/35 fractions. There were 38% grade3 toxicities. Also the complete 
response and partial response in this study was 41% and 50%.the OS at 
1yr and 2yr was 69% and 66% respectively. Though the authors state that 
this as a feasible study with high compliance, this study as low complete 
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response rate of only 41%. This is due to the fact that total cumulative 
dose of cisplatin was less than 200mg/m2. Also study population could 
tolerate weekly 5FU, increased toxicities lead to treatment breaks.78 
 
CAPECITABINE: 
 Capecitabine oral prodrug of 5FU, antimetabolite acts as a potent 
radiosensitizer. Capecitabine is used as a single agent in head and neck 
squamous cell carcinoma. Its role in metastatic and recurrent head and 
neck cancer is well established. Capecitabine as a single agent 
concurrently with radiation in recent trials and it as proved its superior 
efficacy in the form of higher complete response, less toxicity compared 
to weekly cisplatin. 
 
 But the dose of Capecitabine when used concurrently is reduced to 
500mg/m2 twice daily. Also Capecitabine acts as a targeted therapy with 
its rate limiting enzyme thymidine phosphorylase expressed at higher 
levels in tumors with hypoxia, acidosis and low pH. This is the condition 
in most of the solid tumors especially head and neck cancers. Thus the 
concentration of Capecitabine in tumor cell is 2.9 times higher than the 
normal tissues, reducing normal tissue toxicity. This is proved in various 
pharmacokinetic studies and trials with only Capecitabine with 
conventional radiation. 
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 Cisplatin and Capecitabine have been used in three weekly 
regimens in various trials and the efficacy of this regimen is less toxic 
compared to cisplatin and 5FU. The response rates of this regimen are 
also better than cisplatin and 5FU. Though it is less toxic compared to 
cisplatin and 5FU, there was higher grade 3 and 4 toxicities and treatment 
breaks which resulted in poor compliance of the patients. Also despite the 
use various chemotherapy regimens in head and neck the loco regional 
failure is a complicated issue. 
 
 This present study was formulated with the idea of using potent 
chemotherapy drug with radiosensitization which might have a better 
toxicity profile, better loco regional control with good response rates. 
 
 This study of concurrent chemoradiation with weekly cisplatin and 
Capecitabine has shown better locoregional control rates with complete 
response rates of 73% and partial response rate of 27% this is higher 
compared to weekly cisplatin single agent trial which as complete 
response rate of 62% conducted in our department. 
 
 There was no static or progressive disease in this study. Also all 
patients completed their entire chemoradiation schedule. Other trials 
using cisplatin and Capecitabine are already discussed.  
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Table no:28, Capecitabine trials 
AUTHOR RADIATION CHEMOTHERAPY 
RESPONSE/ 
TOXICITY 
Sherif A. 
Raafat et al 
66 – 70Gy in 2Gy 
per fraction,33-35 
fractions 
Cisplatin 
30mg/m2weekly Vs 
Capecitabine 
500mg /m2 twice 
daily 
CR with cisplatin is 
60% Vs 
Capecitabine as CR 
of 77% 
Toxicity – 
mucositis in 93% 
of Capecitabine 
group Vs 57% in 
cisplatin group. 
JG Kim et al 
70 Gy in 2 Gy per 
fraction. 
cisplatin of 80 
mg/m2 on day 1 and 
oral capecitabine 
825 mg/m2 twice 
daily from day 1 to 
14 at 3-week 
intervals 
complete responses 
(78.4%) and  
partial responses 
(16.2%)Grade 3 
mucositis in 67.6, 
dermatitis grade ¾ 
in24.3%. hand foot 
mouth syndrome in 
2 patients. 
 
SUBSET ANALYSIS:  
 In this present study the complete response was 73% and partial 
response was 27%. 
 
  Age at diagnosis had a significant effect on response outcome, 
people aged less than 50yrs 80% had complete response. In case of above 
50yrs only 66% had complete response. This could be explained as young 
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age patients had good general condition, nutrition status and performance 
status. 
 
 The male population dominated the study with80%, this can be 
explained due to the habits of tobacco and alcohol in male patients. The 
response rate also higher in males with 75% had complete response in 
contrast to 66% of the females. 
 
 All patients in this study belonged to performance status ECOG 0 
or 1. Both the group had more less equal response rates. So performance 
status wise significance in difference could not be made out. 
 
 As the site of primary tumor is considered Larynx as 100% CR 
(supraglottis) followed by oropharynx with CR 77% and Hypopharynx 
with CR 62.5%. the Cr in oral cavity was comparatively less of 57% with 
high   partial response 42.5% compared to other sub sites. This can be 
explained due to the fact that Oral cavity lesions are well differentiated 
tumor, so their response to Chemo RT is inferior than moderately or 
poorly differentiated histology. This study also showed similar results 
with poorly differentiated high CR > moderately > well differentiated 
histology. 
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 The response rate in the primary site and nodal region was different 
inn this study. At the primary site CR was 73% whereas in that of the 
nodal region was 87%. Also N3 disease showed only partial response. 
 
 The T4a lesion due to its extensive infiltrative lesions had 33% 
partial response compared to 25% partial response in T3 lesion. Though 
there is high partial response in T4a due to hypoxia, necrosis of tumor 
burden this is comparatively less in total partial response in which it 
accounts only 13%. 
 
 The primary objective of this study was to determine the 
locoregional control as discussed above. As the sample size was small, 
statistical analysis is questionable for its significance. 
 
 The secondary objective of this study is the toxicity assessment. 
As showed in trials cisplatin and Capecitabine in full dose three weekly 
schedules as grade 3 and 4 toxicity. But in this present we use weekly 
cisplatin and Capecitabine low dose continuously concurrent radiation 
showed manageable toxicity. Mucositis is usually increased in concurrent 
chemoradiation trials in same way this study also showed grade 2 
mucositis 40%, grade 3-16% and grade 4- 6%.  Grade 4 mucositis needed 
treatment to resolve and again proceeded with complete treatment. This is 
attributed to the additional effect of radiotherapy that too patients are 
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treated with Cobalt 60 and not in 3DCRT, IMRT. Also all patients had 
dermatitis grade 1 in 76.66% of patients and grade 3 in 6% of patients. 
These can be explained because of the radiosensitising effect of cisplatin 
and Capecitabine. 
 
 There was no Hand foot syndrome in the patients of this study. 
Nausea and vomiting was also grade 1 and self-limiting in most patients.  
 
 Also diarrhea major side effect of 5FU was seen in only 6% of 
patients. It was only grade 1 diarrhea and treated with antimotility drugs. 
There was no dehydration in any patients. 
 
 All patients were hydrated properly during chemoradiation and 
thus none of the patients had renal toxicity. 
 
 There wasn’t any thrombocytopenia among study patients. There 
was only 10% of the patients had grade 1 Leucopenia and managed 
accordingly. Anemia grade 2 in 13.3% of patients and packed cell 
transfusion was given. Most of our patients are from low socioeconomic 
status, anemia may be explained due to nutritional deprivation. 
 
 There wasn’t any treatment related deaths in this study. 
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Merits of this study:  
 All patients had locally advanced head and neck squamous 
cell caracinoma, the treatment of choice is concurrent 
chemoradiation, was given. 
 Optimal tumoricidal dose of 66Gy was administrated. 
 Optimal dose of weekly cisplatin > 200mg/m2 was achieved 
in all patients. 
 Capecitabine toxicity of hand foot syndrome didn’t occur in 
any patients. 
 The chemotherapy in weekly schedule assisted to strict 
regular monitoring of toxicity reactions. 
 Toxicities were manageable. No treatment related death 
occurred in this study. Toxicity were graded with RTOG 
Acute radiation morbidity scoring criteria and CTCAE 
version 4.03 
 Response assessment was done after 4-6weeks of completion 
of chemoradiation, RECIST 1.1 criteria was used for 
assessment. 
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DEMERITS OF THIS STUDY: 
 There wasn’t long term follow up of this study, so progression free 
survival, overall survival could not be assessed. 
 Radiation delivery was given through 2D technique. 
 This is a single arm phase two trial, hence double armed study and 
randomized control trial must follow to determine prognostic 
significance and survival rates. 
 
Future perspective:  
This study further established the feasibility and efficacy of 
concurrent  Capecitabine and weekly Cisplatin with radiation in locally 
advanced head and neck cancers. Randomized trial using the same 
protocol is recommended. 
 
 
 
 
  
  
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
The head and neck cancer burden is a distressing problem in the 
developing countries like India. Inspite of the effective ban on the 
tobacco usage, the consumers of tobacco and alcohol is rising. Also most 
of our people are in low socioeconomic status, illiterate and lack of 
awareness of medical attention; makes people to present in locally 
advanced stage. Hence locoregional control becomes a challenge. Many 
concurrent chemoradiation trials are upcoming in head and neck 
squamous cell carcinoma. 
 
 The aim of this study was to evaluate and explore Capecitabine and 
weekly cisplatin concurrently with conventional radiation. The dose of 
weekly cisplatin 40mg/m2 and Capecitabine 500mg/m2 twice bid has 
shown effective locoregional control with a complete response of 73% 
and partial response was 27% with manageable toxicity. 
 
 Though there is lack of long term follow up of this study, 
locoregional control was effective. Large scale randomized study are 
recommended in near future for PFS and OS. 
 
 This study of concurrent chemoradiation with Capecitabine and 
weekly cisplatin is a feasible option in our patients with manageable 
toxicity. 
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APPENDIX 1 
TABLE NUMBER TITLE 
1 Cancer trend 
2 Head and neck cancer Site (1) 
3 Head and neck cancer site (2) 
4 Age distribution of study population 
5 Gender distribution of study 
population 
6 ECOG performance status 
7 Habits/ addiction of the study 
population 
8 Symptoms / Signs 
9 Primary site 
10 Subsite analysis 
11 Tumor Tstage 
12 Nodal N Stage 
13 Stage grouping 
14 Histological differentiation 
 
15 Response results 
16 Site Vs response 
17 T stage Vs response 
18 N nodal stage Vs Response 
19 Histological response Vs Response 
20 ECOG Vs Response 
21 Age Vs response 
22 Stage Vs response 
23 Treatment Vs response 
24 Acute Toxicity 
25 Systemic toxicity 
26 Anemia 
27 Cisplatin Response 
28 Capecitabine trials 
 
  
APPENDIX 2 
FIGURE TITLE 
1 HPV biological action 
2 Lymph nodes levels 
3 Age distribution of the study 
population 
4 Gender distribution of the study 
population 
5 ECOG performance status 
6 Symptoms and signs 
7 Site distribution of the study 
population 
8 Subsite Analysis 
9 T stage in the study population 
10 Nodal stage in the study population 
11 Stage grouping 
12 Treatment results - Response 
13 Site Vs Response 
14 T stage Vs Response 
15 Nodal stage vs Response 
16 Histologic differentiation Vs Response 
17 Response in the Primary 
18 Response in the Nodes 
19 Treatment delay 
20 Response Vs Treatment break 
21 Acute toxicity 
22 Systemic Toxicity 
23 Hematological Toxicity 
 
  
APPENDIX 3 
RTOG ACUTE RADIATION MORBIDITY CRITERIA 
SITE  GRADE 0 GRADE1 GRADE2 GRADE3  GRADE 4 
SKIN No 
change 
over 
baseline  
 
Follicular, faint 
or dull 
erythema/ 
epilation/dry 
desquamation/ 
decreased 
sweating  
 
Tender or 
bright 
erythema, 
patchy moist 
desquamatio
n/ moderate 
edema  
 
Confluent, 
moist 
desquamati
on other 
than skin 
folds, 
pitting 
edema  
 
Ulceration, 
hemorrhage, 
necrosis  
 
Mucous 
Membran
e  
 
No change 
over 
baseline  
 
Injection/ may 
experience mild 
pain not 
requiring 
analgesic  
 
Patchy 
mucositis 
which may 
produce an 
inflammator
y 
serosanguinit
is discharge/ 
may 
experience 
moderate 
pain 
requiring 
analgesia  
 
Confluent 
fibrinous 
mucositis/ 
may include 
severe pain 
requiring 
narcotic  
 
Ulceration, 
hemorrhage 
or necrosis  
 
SALIVARY 
GLAND  
 
No change 
over 
baseline  
 
Mild mouth 
dryness/ slightly 
thickened 
saliva/ may 
have slightly 
altered taste 
such as metallic 
taste/ these 
changes not 
reflected in 
alteration in 
baseline feeding 
behavior, such 
as increased use 
of liquids with 
meals 
Moderate to 
complete 
dryness/ 
thick, sticky 
saliva/ 
markedly 
altered taste  
 
 Acute 
salivary 
gland 
necrosis  
 
Pharynx 
& 
Esophagu
s  
 
No change 
over 
baseline  
 
Mild dysphagia 
or odynophagia/ 
may require 
topical 
anesthetic or 
non-narcotic 
analgesics/ may 
require soft diet  
 
Moderate 
dysphagia or 
odynophagia
/ may require 
narcotic 
analgesics/ 
may require 
puree or 
liquid diet  
 
Severe 
dysphagia or 
odynophagia 
with 
dehydration or 
weight 
loss(>15% 
from pre-
treatment 
baseline) 
requiring  
N-G feeding 
tube, I.V. 
fluids or hyper 
alimentation  
 
 
Complete 
obstruction, 
ulceration, 
perforation, 
fistula  
 
Laryngitis  
 
No change 
over 
baseline  
 
Mild or 
intermittent 
hoarseness/cou
gh not requiring 
antitussive/ 
erythema of 
mucosa  
 
Persistent 
hoarseness 
but able to 
vocalize/ 
referred ear 
pain, sore 
throat, 
patchy 
fibrinous 
exudate or 
mild 
arytenoid 
edema not 
requiring 
narcotic/ 
antitussive  
 
Whispered 
speech, throat 
pain or 
referred ear 
pain requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid 
edema  
 
Marked 
dyspnea, 
stridor or 
hemoptysis 
with 
tracheosto
my or 
intubation 
necessary  
 
 
 
 
 
 
HEMATOLOGIC TOXICITY 
Grade  
 
0 1 2 3 4 
HEMATOLOGIC 
WBC (X 1000)  
 
>=4.0  
 
3.0 - <4.0 
 
2.0 - <3.0  
 
1.0 - <2.0  
 
<1.0  
PLATELETS  
(X 1000)  
 
>=100  
 
75 - <100  
 
50 - <75  
 
25 - <50  
 
<25 or 
spontaneous 
bleeding  
NEUTROPHILS  
 
>=1.9  
 
1.5 - <1.9  
 
1.0 - <1.5  
 
0.5 - <1.0  
 
<0.5 or 
sepsis  
 
HEMOGLOBIN 
(GM %)  
>11 
 
11-9.5  
 
<9.5 - 7.5  
 
<7.5 - 5.0  
 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 4 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
CTCAE VERSION 4 
GRADE 1 2 3 4 
Nausea  
 
Loss of appetite 
without 
alteration in 
eating habits  
 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration or 
malnutrition  
 
Inadequate oral 
caloric or fluid 
intake, tube feeding, 
TPN, or 
hospitalization 
indicated  
 
- 
Vomiting  
 
 1-2 
episodes  
(separated 
by 5 
minutes) in 
24 hrs 
 
3-5 episodes 
(separated 
by 5 
minutes) in 
24 hrs 
 
>/=6 episodes 
(separated by 5 
minutes) in 24 
hrs,tubefeeding,TPN 
or hospitalization 
indicated  
 
Life-
threatening 
consequences, 
urgent 
intervention 
indicated  
 
Diarrhea Increase of <4 
stools per day 
over baseline; 
mild increase in 
ostomy output 
compared to 
baseline 
Increase of 4 -
6 stools per da 
over baseline; 
moderate 
increase in 
ostomy output 
compared to 
baseline 
Increase of =7 stools 
per day 
over baseline; 
incontinence; 
hospitalization 
indicated;severe 
increase in ostomy 
output 
compared to 
baseline; limiting 
self care ADL 
Life-
threatening 
consequences; 
urgent 
intervention 
indicated 
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 ANNEXURES I 
INFORMATION TO PARTICIPANTS 
Title: -    “CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED 
SQUAMOUS CELL CARCINOMA OF HEAD AND NECK  WITH  CAPECITABINE 
AND WEEKLY CISPLATIN“ 
 
Principal Investigator:  
Co-Investigator:  Dr. Ramya.A. 
Name of Participant: 
Site :Department of radiotherapy 
You are invited to take part in this research/ study/procedures/tests. The information in 
this document is meant to help you decide whether or not to take part. Please feel free to ask if 
you have any queries or concerns. 
What is the purpose of research? 
Head and neck cancer is widely prevalent in India, and about 16% cancer related 
deaths are due to head and neck cancer. Majority of the patients present with a locoregionally 
advanced disease where the management becomes quite challenging. The oral 
fluoropyrimidinecapecitabine was rationally designed  to preferentially generate 5 -FU in 
tumour tissue and mimic continuous-infusion 5 -FU. This selectivity is achieved through 
exploiting the significantly higher activity of thymidine phosphorylase (TP) in many tumour 
tissues compared with healthy tissue.  
 Concurrent chemoradiotherapy - Radiotherapy will be delivered by opposing lateral 
fields with a telecobalt machine in 200cGy per fraction for 5 days a week. Patients are given 
a break on Saturday and Sunday. Weekly Cisplatin chemotherapy is given every Monday 
before radiation and Tab. Capecitabine daily. Entire treatment is to be completed in less than 
7 weeks time. Primary and gross adenopathy receive 66 Gy 
We have obtained permission from the Institutional Ethics Committee.  
The study design 
Single arm prospective study 
 
Study Procedures 
 
The study involves evaluation of Locally advanced squamous cell carcinoma of the head and 
neck with radiotherapy and chemo in the form weekly inj.cisplatin and daily tab.capecitabine. 
Every week before chemotherapy, the study physician will examine you. Some [blood / urine 
/clinical examination other] tests will be carried out at each visit. [… … ml of blood will be 
collected at each visit. Blood collection involves prick with a needle and syringe.] These tests 
are essential to monitor your condition, and to assess the safety and efficacy of the treatment 
given to you. 
In addition, if you notice any physical or mental change(s), you must contact the persons 
listed at the end of the document.  
 
You may have to come to the hospital (study site) for examination and investigations apart 
from your scheduled visits, if required.  
 
Possible benefits to other people  
 
The results of the research may provide benefits to the society in terms of advancement of 
medical knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical history). 
By signing this document, you will be allowing the research team investigators, other study 
personnel, sponsors, Institutional Ethics Committee and any person or agency required by 
law like the Drug Controller General of India to view your data, if required. 
The information from this study, if published in scientific journals or presented at scientific 
meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical care or 
your relationship with the investigator or the institution. You will be taken care of and you 
will not lose any benefits to which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to withdraw from 
this study at any time during the course of the study without giving any reasons. However, it 
is advisable that you talk to the research team prior to stopping the treatment/discontinuing of 
procedures etc. 
 
 
Signature of Investigator                                                                      Signature of Participant   
Date                                                                                                      Date 
 
 
 
 
 
 
ANNEXURES II 
INFORMED CONSENT FORM 
TITLE OF THE STUDY :“CONCURRENT CHEMORADIOTHERAPY IN LOCALLY 
ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK WITH 
CAPECITABINE AND WEEKLY CISPLATIN NAME OF THE PARTICIPANT: 
 
NAME OF THE PRINCIPAL (Co – Investigator) : DR.A.RAMYA,  
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
 
_____________________________ have read the information in this form (or it has been read to me). 
I was free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a participant in 
“CONCURRENT CHEMORADIOTHERAPY IN LOCALLY ADVANCED SQUAMOUS 
CELL CARCINOMA OF HEAD AND NECK WITH CAPECITABINE AND WEEKLY 
CISPLATIN” 
 
1. I have read and understood this consent form and the information provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the investigator. 
5. I have been informed the investigator of all the treatments I am taking or have taken in the past 12 
months including any native (alternative) treatment. 
6. I have been advised about the risks associated with my participation in this study.* 
7. I agree to cooperate with the investigator and I will inform him/her immediately if I suffer 
unusual symptoms. * 
8. I have not participated in any research study within the past  12 month(s). * 
9. I agree to undergo complete blood count, renal and liver function test, chest x ray, CT scan   of the 
head and  neck 
10. I am aware of the fact that I can opt out of the study at any time without having to give any reason 
and this will not affect my future treatment in this hospital. * 
11. I am also aware that the investigator may terminate my participation in the study at any time, for 
any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information obtained from me as result 
of participation in this study to the sponsors, regulatory authorities, Govt. agencies, and IEC. I 
understand that they are publicly presented. 
13. I have understand that my identity will be kept confidential if my data are publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should contact the investigator. By signing 
this consent form I attest that the information given in this document has been clearly explained to me 
and understood by me, I will be given a copy of this consent document 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent) 
Name ________________ Signature_________________ Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent 
Name ________________ Signature_________________ Date________________ 
 
 
ANNEXURES III 
 
Muha;r;rpjfty; jhs; 
 
ஆராய்ச்சியின் பெயர்: 
தலைமற்றும்கழுத்துபகுதியில்உள்ளமுற்றியச்ககோமஸ்செல்வலகபுற்றுக ோய்
க்குகதிர்வீச்சுெிகிச்லெயும்;Nfg;grpl;lhgpd; khj;jpiuமற்றும்; 
வோரம்ஒருமுலறபுற்றுக ோய்மருந்துrp];gpshl;bd; 
சகோடுத்துபுற்றுக ோலயகுணப்டுதுவது 
ஆராய்ச்சியாளர் பெயர்: 
ெங்கேற்ொளர் பெயர்: 
nrd;id ,uh[Pt;fhe;jpmuRnghJkUj;Jtkidf;FtUk; jiykw;Wk; 
fOj;JgFjpGw;WNeha; Nehahspapfsplk; fjph;tPr;Rrpfpr;irgw;wpaMuha;r;rp. 
jiykw;Wk; fOj;JgFjpapy; Kw;wpa Gw;WNeha;f;F gytifahd 
fjph;tPr;Rrpfpr;ir Kiwfs; cs;sd. 
“தலைமற்றும்கழுத்துபகுதியில்உள்ளமுற்றியச்ககோசமௌஸ்செல்வலகபுற்று
க ோய்க்குகதிர்வீச்சுெிகிச்லெயும்;Nfg;grpl;lhgpd;khj;jpiuமற்றும்வோரம்ஒருமு
லறபுற்றுக ோய்மருந்துrp];gpshl;bdk;சகோடுத்துபுற்றுக ோலயகுணப்டுதுவது”
gw;wpMuha;tJ ,e;jMuha;r;rpapd; Nehf;fk;. 
ePq;fSk; ,e;j Muha;r;rpapy; gq;Nfw;f tpUk;GfpNwhk;. ,e;j 
Muha;r;rpapy; fjph;tPr;Rrpfpr;ir kw;Wk;  Gw;WNeha; kUe;J mspj;J rpy 
rpwg;G ghpNrhjidf;F cl;gLj;jp mjd; jfty;fis Muha;Nthk;. mjdhy; 
jq;fspd; Nehapd; Ma;twpf;ifNah rpfpr;irNah ghjpg;G Vw;glhJ vd;gij 
njhptpj;Jf; nfhs;fpNwhk;. 
KbTfis my;yJ fUj;Jf;fis ntspapLkNghNjh my;yJ 
Muha;r;rpapd;NghNjh jq;fspd; ngaiuNah my;yJ milahsq;fisNah 
ntspaplkhl;Nlhk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;.  
,e;j rpwg;G ghpNrhjidfspd; KbTfisAk; Nehapd; jd;ikgw;wpAk; 
Muha;r;rpapd; NghJ my;yJ Muha;r;rpapd; Kbtpd; NghJ jq;fSf;F 
mwptpg;Nghk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 
_______________________________                                       ________________________________ 
Muha;r;rpahsh; ifnahg;gk;    gq;Nfw;ghsh; ifnahg;gk;  
Njjp:    
 
 
ANNEXURES IV 
Muha;r;rpxg;Gjy; fbjk; 
பெயர்:      தேதி: 
 
வயது:      ௨ள்/புற த ோயோளி எண்: 
 
ெோல்:       ஆரோய்ச்சி தேர்க்கை எண்: 
 
nrd;id ,uh[{t;fhe;jp muR nghJ kUj;Jtkidf;F tUk; Gw;WNeha; 
Nehahspapfsplk; fjph;tPr;R rpfpr;ir gw;wpa Muha;r;rp. 
 Jiy kw;Wk; fOj;JgFjpapy; Kw;wpa Gw;WNeha;f;F gytifahd 
fjph;tPr;Rrpfpr;irKiwfs; 
cs;sd.“தலைமற்றும்கழுத்துபகுதியில்உள்ளமுற்றியச்ககோசமௌஸ்செல்வ
லகபுற்றுக ோய்க்குகதிர்வீச்சுெிகிச்லெயும்;Nfg;grpl;lhgpd;khj;jpiu மற்றும் 
வோரம்ஒருமுலறபுற்றுக ோய்மருந்துrp];gpshl;bdk;சகோடுத்துபுற்றுக ோலயகு
ணப்டுதுவது”,e;jMuha;r;rpapd; Nehf;fk;. 
 ePq;fSk; ,e;j Muha;r;rpapy; gq;Nfw;f tpUk;GfpNwhk;. ,e;j 
Muha;r;rpapy; fjph;tPr;Rrpfpr;ir kw;Wk;  Gw;WNeha; kUe;J mspj;J rpy 
rpwg;G ghpNrhjidf;F cl;gLj;jp mjd; jfty;fis Muha;Nthk;. mjdhy; 
jq;fspd; Nehapd; Ma;twpf;ifNah rpfpr;irNah ghjpg;G Vw;glhJ vd;gij 
njhptpj;Jf; nfhs;fpNwhk;. 
 KbTfis my;yJ fUj;Jf;fis ntspapLkNghNjh my;yJ 
Muha;r;rpapd;NghNjh jq;fspd; ngaiuNah my;yJ milahsq;fisNah 
ntspaplkhl;Nlhk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;.  
,e;j rpwg;G ghpNrhjidfspd; KbTfisAk; Nehapd; jd;ikgw;wpAk; 
Muha;r;rpapd; NghJ my;yJ Muha;r;rpapd; Kbtpd; NghJ jq;fSf;F 
mwptpg;Nghk; vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;. 
 
 
_______________________________                                       ________________________________ 
Muha;r;rpahsh; ifnahg;gk;    gq;Nfw;ghsh; ifnahg;gk; 
Njjp:    
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